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1. INTRODUCTION 
1.1 Apoptosis 
Apoptosis, also called ‘programmed cell death’, is a highly evolutionally conserved 
mechanism aimed to remove excess-cells from an organism. It plays an important role in 
physiological processes such as development, during organogenesis, and in adult tissues 
homoeostasis, controlling cell proliferation, lymphocytes selection within the immune system 
and elimination of old, differentiated cells with self-renewal capacity. Dysregulation of 
apoptosis has been implicated in various human diseases, including cancer, autoimmunity and 
neurodegenerative disorders (Thompson C.B. 1995). 
Apoptosis is characterized by a series of morphological changes, which include plasma 
membrane blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation and 
chromosomal DNA fragmentation, eventually leading to vesicles (‘apoptotic bodies’) 
formation and their rapid phagocytosis (Kerr J.F. et al 1972). Apoptosis can be triggered by 
two main pathways: the extrinsic or ‘death receptor-mediated’ pathway and the intrinsic or 
‘mitochondrial’ pathway (Hengartner M.O. 2000) (Figure 1.1). 
1.1.1 The extrinsic or ‘death receptor-mediated’ pathway 
The extrinsic or ‘death receptor-mediated’ pathway is activated by the binding of 
characteristic molecules, such as the Fas-ligand (or CD95L), TRAIL and TNF-α, to the 
surface receptors of the plasma membrane, called ‘death receptors’ or DRs, which mainly 
include members of the TNF receptor protein superfamily (e.g. CD95 or Fas/Apo1, TRAIL-
R1 and TNF-R1) (Ashkenazi A. et al 1998). DRs contain an intracellular death domain (DD) 
which is able, after oligomerization with other DDs, to recruit adaptor molecules such as 
FADD. Adaptor molecules, in turn, recruit procaspase-8 through their death effector domain 
(DED) to form the DISC complex, where oligomerization and auto-proteolytic cleavage of 
caspase-8 occur, eventually leading to activation of downstream effector caspases, such as 
caspase-3 and 7 (Walczak H. et al 2000). Caspase-8 can also indirectly trigger the intrinsic 
pathway of apoptosis by cutting the BH3-only protein Bid at the C-terminal level (Li H. et al 
1998). Truncated Bid (t-Bid) is then transferred to mitochondria, where it initiates the outer 
mitochondrial membrane (OMM) permeabilization through interaction with other Bcl-2 
proteins (see below). 
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1.1.2 The intrinsic or ‘mitochondrial’ pathway 
The intrinsic or ‘mitochondrial’ pathway is triggered by endogenous stress signals such as 
DNA damage, viral infection and growth-factor deprivation. It is regulated by the Bcl-2 
protein family (Tsujimoto Y. 2003, Vaux D.L. et al 1988). Bcl-2 family comprehends more 
than 30 proteins, sharing a strict homology due to the presence of specific regions, called Bcl-
2 homology (BH) domains. Based on their function and domains distribution, Bcl-2 proteins 
can be divided in 3 sub-groups: the anti-apoptotic factors (e.g. Bcl-2, Bcl-xL, Mcl-1), the pro-
apoptotic factors (Bax and Bak) and the pro-apoptotic ‘BH3-only’ proteins (e.g. Bid, Bim, 
Noxa, Puma) (Youle R.J. et al 2008). Both the Bcl-2-like anti-apoptotic proteins and the pro-
apoptotic ones possess four short, highly conserved BH domains (BH1-4), while the third 
group contains, as the name suggests, only the BH3 domain, and is much more 
heterogeneous. Anti-apoptotic factors and pro-apoptotic Bax and Bak share a very similar 
tridimensional structure, with 3 BH domains (BH1-3) interacting to form a hydrophobic 
groove on the surface of the protein, stabilized by the fourth BH4 domain (Muchmore S.W. et 
al 1996, Sattler M. et al 1997). This pocket represents the critical site for the interaction and 
inhibition of pro-apoptotic factors by their anti-apoptotic partners. Upon apoptotic stimuli, 
Bax and Bak are released from the anti-apoptotic proteins and insert 2 helices in the OMM, 
oligomerize and promote the release of pro-apoptotic proteins from the inter-membrane space 
(IMS) through the formation of pores (Antonsson B. et al 2000). Before the beginning of the 
process, Bak is already anchored to the OMM or the endoplasmic reticulum (ER), while Bax 
has to be translocated from the cytosol to the OMM (Cory S. et al 2002). The release of pro-
apoptotic factors from their anti-apoptotic partners can be regulated by the BH3-only proteins 
in two ways. In the first case, “direct activators” BH3-only proteins are released from anti 
apoptotic proteins via their ‘sensitizer’ BH3-only cooperators, and directly interact with Bax 
and Bak, which undergo a conformational change exposing the C-terminal α-helix, allowing 
their targeting to the mitochondria (Korsmeyer S.J. et al 2000). In the second model, BH3-
only proteins can sequester the anti-apoptotic Bcl-2 factors, promoting the function of the 
constitutively active Bax (or Bak) (“derepressor model”) (Willis S.N. et al 2007). The 
“embedded together” model was further proposed, which integrates the first two and 
considers anti-apoptotic factors inhibiting both BH3-only proteins and effectors Bax and Bak. 
Sensitizer BH3-only proteins then relieve this inhibition (Leber B. et al 2007).  
The structural similarities between multi-domain Bcl-2 proteins like Bax and bacterial pore-
forming toxins suggest that Bax, alone, is able to form channels in the OMM (Muchmore 
S.W. et al 1996). Patch clamp studies of Bak pores led to the description of a channel 
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structure called the mitochondrial apoptosis-induced channel (MAC) (Martinez-Caballero S. 
et al 2009), whose properties are consistent with progressive incorporation of activated Bax 
dimers into a Bax pore. Moreover, it has been postulated that Bax oligomers could also induce 
the mitochondrial outer membrane permeabilization (MOMP) by promoting the opening of 
pre-existing pore structures, such as the permeability transition pore (PTP) (Baines C.P. et al 
2005). Bax was also suggested to interact with different proteins of the OMM, such as the 
voltage-dependent anion channels (VDAC) (Baines C.P. et al 2007) and the components of 
the fusion and fission machinery (Martinou J.C. et al 2011, Montessuit S. et al 2010). The 
transporter of the outer membrane complex (TOM) has also been proposed as possible Bax 
receptor (Ott M. et al 2009). Further, evidences exist that lipidic, and not only proteinaceous 
channels are formed. In this case, it has been suggested that Bax or Bak could act in a toxin-
like manner, inducing specific micelle structures in the membrane, eventually resulting in 
lipidic pores (Basanez G. et al 2002, Qian S. et al 2008, Satsoura D. et al 2012).  
Further data suggest that Bax could also interact with the endoplasmatic reticulum (ER) and 
sphingolipid metabolites (Chipuk J.E. et al 2012). Particularly, the group of Green and 
colleagues discovered that contaminants originating from the endoplasmic reticulum in 
mitochondria preparation contained a MOMP-promoting factor, from which a neutral 
sphyngomyelinase was purified and identified to be responsible of t-Bid and Bax (or Bak)- 
induced membrane permeabilization (Chipuk J.E. et al 2012). Further investigations showed 
physical interaction and cooperation between Bax (and Bak) in the membrane and 
sphingolipid products. Moreover, inhibitors of the sphingolipid metabolism were shown to 
block MOMP in membrane preparations. Ganesan and colleagues demonstrated that 
ceramides and Bax can act synergistically to promote membrane permeabilization in rat liver, 
yeast mitochondria and phospholipids membranes, with a lower Bax concentration required to 
achieve maximal MOMP when ceramide is present (Ganesan V. et al 2010b). Conversely, 
ceramide-induced permeabilization of OMM was shown to be inhibited by the addition of 
Bcl-xL (Di Paola M. et al 2000). A colocalization of Bax and ceramide enriched 
microdomains was found in mitochondria (Martinez-Abundis E. et al 2009) and several 
studies demonstrated that it is possible to permeabilize isolated mitochondria by ceramide 
addition (Ganesan V. et al 2010a). However, it is known that activated Bax can induce protein 
release without requiring ceramide (Jurgensmeier J.M. et al 1998). Another work suggested 
that Bax could raise the activity of ceramide synthase, explaining why Bax/Bak knockout 
cells, besides being refractory to apoptosis, fail to elevate cellular levels of ceramide (Siskind 
L.J. et al 2010). Thus, the main aspect, which still needs to be further investigated, is the 
involvement of ceramide channels formation in MOMP. This is strongly supported by the 
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regulation of these channels by the Bcl-2 family proteins, which could act on their stability 
influencing the dynamic equilibrium between different ceramide forms (Ganesan V. et al 
2010a, Ganesan V. et al 2010b). 
The role of cardiolipin, a mitochondrial membranes specific lipid, was also pointed out in 
pores formation, since different studies found its requirement in t-Bid/Bax-induced liposomes 
permeabilization (Kuwana T. et al 2002, Terrones O. et al 2004). However, as for ceramide, it 
is still under debate whether or not cardiolipin is required for MOMP in vivo, since its 
concentration in the OMM is low, being primarily found in the IMM. It could be that 
cardiolipin becomes enriched in OMM-IMM contact sites (Lutter M. et al 2001). Another 
possibility is that OMM proteins, such as the TOM complex or the fusion-fission machinery 
proteins, could substitute the lipid in this role (Ott M. et al 2009). 
MOMP culminates in the release of soluble proteins, such as cytochrome c and Smac, from 
the IMS to the cytosol (Liu X. et al 1996). Cytochrome c forms the apoptosome cytosolic 
complex together with Apaf-1 and the pro-caspase 9 in presence of dATP. The activity of 
caspase-9 (but also of others caspases) is normally suppressed by the inhibitors of apoptosis 
(IAP) proteins such as XIAP and survivin, which are in turn inhibited by Smac/DIABLO 
(Fulda S. et al 2012). Activated caspase-9 is then released from the IAPs, proteolyses caspase-
3 and 7, triggering the executive pathway of apoptosis as in the extrinsic pathway. As 
mentioned above, caspase-3 can be also directly activated by caspase-8, consequently to the 
translocation of tBid to mitochondria, thus determining the cross talk between the intrinsic 
and extrinsic pathways. Beyond apoptosome formation promoting factors, mitochondria also 
release intermembrane proteins, such as AIF and endonuclease G which, upon translocation to 
the nucleus, can directly cause large-scale DNA fragmentation and chromatin condensation, 
independently of caspases (Li L.Y. et al 2001, Susin S.A. et al 1999). 
Figure 1.1. Intrinsic and extrinsic pathways in apoptosis. The instrinsic apoptotic pathway can be initiated by 
exposure to stress signals such as growth factor deprivation, radiation or viruses, which in turn activate the BH3-
only proteins. Activated BH3-only proteins can trigger the release of pro-apoptotic proteins Bax and Bak by 
direct interaction with them or by releasing them from their anti-apoptotic partners (e.g.: Bcl-2). Released Bax 
and Bak insert 2 helices in the outer mitochondrial membrane (OMM), where they oligomerize and promote the 
release of pro-apoptotic proteins, such as cytochrome c, and mitochondrial fragmentation. This leads to the 
activation of APAF-1 into the apoptosome complex, which in turn activates caspase 9. Activated caspase 3 by 
caspase 9 cleaves other substrates, activates DNases and triggers apoptosis. The extrinsic pathway is initiated by 
the binding of specific molecules to the death receptors of the TNF superfamily (e.g. TNFR1, CD95). This leads 
to activation of caspase-8, which triggers activation of effector caspases, such as caspase-3. Activated caspase-8 
can also indirectly initiate the intrinsic apoptotic pathway by cleaving the BH3-only protein Bid, which is 
translocated to the mitochondria and triggers the OMM permeabilization by inhibiting the anti-apoptotic proteins 
or by activating the pro-apoptotic ones (adapted from (Youle R.J. et al 2008)). 
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1.2 Kv1.3 
Kv1.3, or “potassium voltage-gated channel, shaker-related subfamily, member 3” is a 63 
KDa transmembrane protein, first discovered in human T lymphocytes (Cahalan M.D. et al 
1985, DeCoursey T.E. et al 1984, Grissmer S. et al 1990, Matteson D.R. et al 1984), where it 
was shown to be, along with the less expressed calcium-activated potassium channel KCa3.1 
(Grissmer S. et al 1993), the main K
+
 channel. First cloned from rat brain (Swanson R. et al 
1990), in humans it is encoded by the KCNA3 gene (Douglass J. et al 1990), which appears to 
be intronless and is localized on chromosome 1 (Chandy K.G. et al 1990). Kv1.3 belongs to 
the Shaker family of voltage-gated channels (Gutman G.A. et al 2005), the name of which 
refers to the atypical behavior seen in Drosophila melanogaster subsequent to the shaker (sh) 
gene mutation (Salkoff L. et al 1981).  
Voltage gated potassium channels (Kv) represent, in humans, the largest family of potassium 
(K
+
) channels and comprehend at least 40 genes, divided in 12 subfamilies (Kv1-Kv12). They 
are sensitive to the voltage changing in the cell’s membrane potential and they open 
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consequently to a membrane depolarization: K
+
 ions flow out following their electrochemical 
gradient ([K
+
] in >> [K
+
] out), eventually leading to a hyperpolarization of the membrane. Kv 
channels share, as all K
+
 channels, a homo- or hetero-tetrameric structure, constituted by 4 
subunits (α), each characterized by 6 transmembrane helices (S1–S6) with both the N-
terminus and C-terminus located in the intracellular side of the membrane (Bright J.N. et al 
2002) (Figure 1.2). The channel voltage sensor is formed by the first 4 helices (with the S4 
helix containing four positively charged arginine residues acting as voltage-sensor domain) 
(Long S.B. et al 2007), while the pore region is given by the last two helices (S5-S6), together 
with a distinctive P-loop structure formed by 5 conserved amino acidic residues (GYGD), and 
representing the selectivity filter for K
+
 (Treptow W. et al 2004, Tytgat J. 1994). In particular, 
the accessibility of K
+
 to the filter is given by the four electronegative carbonyl oxygen atoms, 
exposed by the four residues, which mimic the ion hydration sphere, allowing K
+
 to overcome 
the membrane lypophilicity barrier (Aiyar J. et al 1996). Current properties of Kv channels 
differ based on additional regulatory subunits (e.g. β, γ and δ) associating around the ion 
conducting central pore. Further, post-translational modifications and alternative splicing also 
contribute to the functional diversity of Kv channels (Gutman G.A. et al 2005).  
 
Figure 1.2. Kv channel structure. Molecular structure of one α-subunit of Kv channels (above) and the 
functional tetramer (below). Kv channels are composed by a homo- or hetero-tetrameric structure constituted by 
4 subunits (α). Each subunit is characterized by 6 trans-membrane helices (S1-S6), with both N- and C- terminus 
in the intracellular side of the membrane. The first 4 helices form the channel voltage sensor, with the fourth, S4 
INTRODUCTION 
7 
helix containing four positively charged arginine residues, thus acting as voltage-sensor domain. The last two 
(S5-S6) helices constitute the pore region, containing a distinctive P-loop structure formed by 5 conserved 
aminoacids, which represent the selectivity filter for K
+
. Additional regulatory subunits (e.g. β) can associate 
around the ion conducting pore, thus differently contributing to channel current properties (D'Amico M. et al 
2013).  
 
Kv1.x channels (or mammalian Shaker family), to which Kv1.3 belongs, are largely 
expressed and control the frequency of action potential in the central nervous system (CNS), 
where most of the eight known pore forming subunits (Kv1.1-Kv1.8) have been shown to 
form heteromultimers, containing at least one Kv1.1 and/or Kv1.2 subunit (Coleman S.K. et 
al 1999). Moreover, Shaker family is also present in different peripheral tissues, included 
heart, vessels and immune system. Particularly, Kv1.5 plays a critical role in the atrial action 
potential repolarization (Wettwer E. et al 2004). 
Beyond T lymphocytes, Kv1.3 has been demonstrated to be present in the plasma membrane 
(PM) of several tissues and cells types (Gutman G.A. et al 2005) including brain, lung, 
tonsils, islets, lymph node, thymus, testis, liver, spleen, kidney, skeletal muscle, epithelia 
(Grunnet M. et al 2003), fibroblasts, platelets (Maruyama Y. 1987), CNS (Mourre C. et al 
1999), hippocampal neurons (Bednarczyk P. et al 2010), astrocytes (Cheng Y. et al 2010), 
oligodendrocytes (Chittajallu R. et al 2002), osteoclasts (Arkett S.A. et al 1994), brown and 
white fat (Xu J. et al 2003), macrophages (Mackenzie A.B. et al 2003, Vicente R. et al 2003) 
and B lymphocytes (Gutman G.A. et al 2003, Szabo I. et al 2005). 
Together with the other members of the Kv family, Kv1.3 controls the resting plasma 
membrane potential, the frequency of action potentials and the neurotransmitter release from 
excitable cells (Shoudai K. et al 2007). Moreover, it regulates cell volume (Lang F. et al 
2004), proliferation (Cahalan M.D. et al 2009) and apoptosis (Szabo I. et al 2010) in non-
excitable tissues (Armstrong C.M. 2003, MacKinnon R. 2003). 
Kv1.3 has been demonstrated to play a crucial role in T cells activation by the use of several 
non-selective K
+
 blockers, like 4-aminopyridine (4-AP) (Chandy K.G. et al 1984, DeCoursey 
T.E. et al 1984). Particularly, Kv1.3 expression is increased to 4- to 5-fold in activated 
CD4
+
/CD8
+
 effector-memory cells (TEM) cells (Wulff H. et al 2003). In contrast, naïve T cells 
and central memory T cells (TCM) upregulate KCa3.1 upon activation (Grissmer S. et al 1993). 
After T-cell receptor activation by antigen, K
+
 efflux through Kv1.3 (or KCa3.1) channel 
hyperpolarizes the PM potential, promoting Ca
2+
 entry through the calcium-release activated 
channel (CRAC). Rise in cytosolic Ca
2+
 concentration induces the translocation of the nuclear 
factor of activated T cells (NFAT) to the nucleus, where it initiates transcription, eventually 
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leading to cytokine secretion and T cell proliferation. If K
+
 efflux through Kv1.3 (and KCa3.1) 
is interrupted, cells depolarize, reducing Ca
2+
 influx, which prevents T cell activation.  
Therefore, Kv1.3 channel has been proposed as a novel mean for therapeutic 
immunosuppression to treat autoimmune disorders in which TEM cells are involved (Chandy 
K.G. et al 2004), such as multiple sclerosis (MS), rheumatoid arthritis (RA), type-1 diabetes 
(Beeton C. et al 2006) and psoriasis (Azam P. et al 2007, Gilhar A. et al 2011). Selective 
blockers have been successfully used in the treatment of autoimmune encephalomyelitis 
(EAE), a model for multiple sclerosis (Beeton C. et al 2001).  Moreover, the lipophilic small 
molecule Kv1.3 inhibitor PAP-1 has been shown to successfully suppress delayed-type 
hypersensitivity (DTH) by preventing TEM activation and migration to inflamed tissue 
(Matheu M.P. et al 2008). This compound has also been efficient in preventing spontaneous 
autoimmune type-1 diabetes in rats, by decreasing intra-islet T cells and macrophage 
infiltration (Beeton C. et al 2006), in the treatment of contact dermatitis, a simple animal 
model for psoriasis (Azam P. et al 2007), and in a SCID mouse psoriasis-xenograft model 
(Kundu-Raychaudhuri S. et al 2014). Recently, PAP-1 has also been demonstrated to suppress 
the development of atherosclerosis by inhibiting exocytosis of cytoplasmic granules from 
CD4
+
/CD28
null
 T lymphocytes in a rat model (Wu X. et al 2015). Moreover, in a xenograft 
model, blockage of Kv1.3 by clofazimine was shown to inhibit human T-cell mediated skin 
graft rejection (Ren Y.R. et al 2008). Kv1.3 also participates in the formation of the 
immunological synapse during antigen presentation, since it appears to be physically coupled 
to the T-cell receptor signaling complex (Panyi G. et al 2004). However, its blockade does not 
prevent the synapse formation (Beeton C. et al 2006).  
During apoptosis induced by CD95/Fas and ceramide, Kv1.3 is tyrosine phosphorylated and 
functionally inhibited in T lymphocytes (Gulbins E. et al 1997, Szabo I. et al 1996). 
Particularly, to study the involvement of Kv1.3 in apoptosis, IL-2 dependent murine cytotoxic 
T lymphocytes (CTLL-2), known to be deficient for Kv1.3, were used (Deutsch C. et al 
1993). Stably transfected CTLL-2 with Kv1.3 (CTLL-2/Kv1.3) were shown to be susceptible 
to apoptosis induced by various stimuli including ceramide, staurosporine, actinomycin D, 
sphingomyelinase and TNF-α, whereas control-transfected CTLL-2 (CTLL-2/pJK) were 
resistant to the same agents (Bock J. et al 2002). Importantly, these findings were also 
confirmed in genetically non-manipulated Kv1.3-expressing cells, including Jurkat 
lymphocytes and activated peripheral blood lymphocytes, where siRNA-mediated 
downregulation of the channel hindered cell death (Szabo I. et al 2008). Kv1.3-deficient mice 
generated by the group of Desir (Xu J. et al 2003) display an increase in platelets number, in 
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accordance with a role of Kv1.3 in apoptosis of platelets or their precursors (McCloskey C. et 
al 2010). However, these mice, despite the crucial role of Kv1.3 in lymphocyte activation, 
show no alterations of the immune system and no defects in either lymphocytes proliferation 
or apoptosis (Koni P.A. et al 2003). Instead, the complete loss of Kv1.3 current in the 
thymocytes of these mice was found together with an upregulation of Kv1 genes and a 
chloride channel, thus suggesting a possible compensatory mechanism.  
Based on experiments with Kv1.3 knockout
 
mice, Kv1.3 has also been suggested to be 
involved in the regulation of energy homeostasis and body weight, but the underlying 
mechanism is still poorly understood (Xu J. et al 2003). Particularly, Kv1.3 blockade seems to 
improve insulin sensitivity in adipose and skeletal muscle by facilitating the translocation of 
the glucose transporter GLUT4 to the PM. The same group demonstrated that deletion of 
Kv1.3 can reduce adiposity and increase lifespan in a genetic model of obesity (Xu J.C. et al 
2004). 
1.2.1 Kv1.3 inhibitors 
Because of its role in T cell activation, Kv1.3 has a well-characterized pharmacology. After 
the discovery that the scorpion venom derived peptide charybdotoxin (ChTx) (Sands S.B. et al 
1989) was able to inhibit Kv channels (but also KCa3.1 channels) at nanomolar concentrations, 
more selective toxins were isolated, such as margatoxin (MgTx) (Garcia-Calvo M. et al 1993, 
Koo G.C. et al 1997) and the sea anemone toxin Stichodactyla (ShK) (Pennington M.W. et al 
1996), which represents the most potent inhibitor of Kv1.3, blocking the channel at high 
affinity (Kd = 11 pM) and showing a 1000-fold higher selectivity with respect to other Kv and 
KCa channels (Kalman K. et al 1998, Rauer H. et al 1999). All these peptides, usually 
containing 18-60 amino acids (3-6 KDa), present a strategic positive amino acid, a lysine, 
which interacts with the overall negative charge imparted by a set of acidic amino acids 
specifically present in the vestibule of Kv channels, occluding the channel pore like a ‘cork a 
bottle’ (Chandy K.G. et al 2001, Yu K. et al 2004). The substitution of the critical lysine with 
neutral residues has shown to reduce the affinity of the toxin for the channel, indicating that 
other residues do not bind efficiently to the channel pore vestibule (Lanigan M.D. et al 2002). 
Other toxins also exist, which approach the channel via the membrane lipid bilayer and 
interact with the voltage sensor (Swartz K.J. et al 1997, Swartz K.J. 2007).  
Besides peptide toxins, small organic molecules were also discovered (200-500 Da), which 
act by binding the inner pore or interfacing between Kv1.3 subunits. Differently from peptide 
inhibitors, they can permeate biomembranes, thus reaching and inhibiting the mitochondrial 
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Kv1.3. Among them, the most potent is Psora-4, a 5-phenylalkoxypsoralen (5-MOP) derived 
from the Ruta graveolens plant, which blocks the channel with EC50=3 nM and a 17-70 fold 
selectivity for Kv1.3 over Kv1 channel family, with the exception of Kv1.5 (Vennekamp J. et 
al 2004) (Figure 1.3). Therefore, a more selective compound was synthesized, PAP-1 (EC50=2 
nM) (Schmitz A. et al 2005). However, patch clamp experiments showed that both inhibitors 
can act also on other Kv channels, if used at higher concentrations. Recently, the already 
known anti-mycobacterial drug clofazimine was found to inhibit Kv1.3 with EC50= 400 nM 
(Ren Y.R. et al 2008). This highly lipophilic drug, belonging to the riminophenazine family, 
has been used since 1960, marketed as Lamprene, to treat various dermatological diseases 
included leprosy (Karat A.B. et al 1970), pustular psoriasis (Chuaprapaisilp T. et al 1978) and 
lupus erythematosus (Mackey J.P. et al 1974). 
 
Figure 1.3. Psora-4 structure, derivative of the major K
+
 channel blocking compound from plant R. Graveolens, 
5-metoxypsoralen (5-MOP), and EC50 values relative to Kv1.3 and Kv1.5 channels (Schmitz A. et al 2005). 
1.2.2 Kv1.3 ‘new inhibitors’: PAP-1 derivatives 
Despite the promising results obtained in vitro, in vivo and ex vivo (Leanza L. et al 2012, 
Leanza L. et al 2013), PAP-1 and Psora-4 are two poorly water soluble and highly 
hydrophobic drugs. Their molecular characteristics limit their use in humans, since only 
relatively high concentrations have to be used to obtain effects. On the other hand, 
clofazimine, even if highly lipophilic, has shown to have a very good safety profile and was 
already administered orally to patients with leprosy and antibiotic resistant tuberculosis 
(Dooley K.E. et al 2013). Furthermore, all these compounds are dissolved in DMSO, which is 
an organosulfur and toxic compound. In collaboration with the group of Prof. C. Paradisi of 
the Department of Chemical Sciences, University of Padua (Italy), PAP-1 derivatives have 
been synthetized both to improve the water solubility and to target an inhibitor to the 
mitochondria. Importantly, all chemical modifications should lead the derivatives still to 
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inhibit Kv1.3. All these improvements will favor their orally bio availability. The ability of 
the compounds to reach mitochondria was augmented. PAP-1 and Psora-4 have a high log P 
(P, partition coefficient), which reflects the tendency of a compound to accumulate in 
biological membranes and serum. This increases the concentration required to reach the 
correct target in the cell and induce cell death. Thus, a positive phosphonium group was added 
to the precursors, allowing the accumulation of the derivatives in mitochondria driven by the 
membrane potential, without a specific mechanism of uptake. In particular, since lipophilic 
cations easily move throughout phospholipid bilayers – because the activation energy required 
for the movement from a biological membrane is far lower than that needed from other 
cations – a TPP (tetraphenylphosphonium) group was added, whose highly lipophilic 
positivity permits the crossing of the membranes, including the highly negative mitochondrial 
one (Sassi N. et al 2012). In this case, two groups have been developed: a first one, in which 
the TPP is covalently bound to the PAP-1 molecule, and a second one, in which TPP is linked 
to the PAP-1 by a carbamate group that can be hydrolyzed, intracellularly releasing the free 
PAP-1. Furthermore, the derivatives have been modified to become more water soluble. This 
was achieved by adding to the PAP-1 four to six PEG (polyethylene glycol) functional 
groups, which are known to improve solubility.  
1.2.3 Mitochondrial Kv1.3 and apoptosis 
Kv1.3 was the first functionally active Kv channel to be identified in the inner mitochondrial 
membrane (IMM) (Szabo I. et al 2005). Mitochondrial Kv1.3 (mtKv1.3) was initially 
characterized in freshly isolated peripheral human blood lymphocytes by using transmission 
electron microscopy and western blot. Functional expression was shown by patch clamp on 
mitoplasts from Jurkat T lymphocytes (Szabo I. et al 2005), known to endogenously express 
Kv1.3 (Cahalan M.D. et al 1985). Channel identity was also determined by using the genetic 
model of CTLL-2 cells transfected with Kv1.3, where colocalization with PTP and the 107-pS 
channel in the IMM was found. Differently from the PM located one, mtKv1.3 seem to be 
active also at very negative voltages (resting potential) of mitochondria, thus contributing to 
the basal K
+
 conductance in mitochondria (Bernardi P. 1999). The presence of the channel 
was further shown in mitochondria of macrophages (Vicente R. et al 2006) and hippocampal 
(Bednarczyk P. et al 2010) and presynaptic neurons (Gazula V.R. et al 2010). 
Although mtKv1.3 is expected, similarly to other IMM K
+ 
channels, to regulate mitochondrial 
membrane potential, volume and ROS production, the role of this channel in physiological 
conditions has not been yet clarified. However, a crucial role for mtKv1.3 in apoptosis has 
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become evident, first in lymphocytes, and then in other systems as well (Szabo I. et al 2008). 
Particularly, it was shown in the CTLL-2 model (see above) that expression of a 
mitochondria-targeted Kv1.3 construct was able to sensitize apoptosis-resistant CTLL-2 T 
lymphocytes, lacking Kv channels, to different apoptotic stimuli (Szabo I. et al 2008). The 
specificity of mtKv1.3 involvement was also shown by the use of membrane-permeable 
Kv1.3 inhibitors Psora-4, PAP-1 and clofazimine, which induced cell death in Kv1.3-
expressing cells, while membrane-impermeable blockers, such as MgTx, did not.  
Among apoptotic stimuli able to induce mtKv1.3-mediated apoptosis, also Bax was found. 
Structural analysis revealed that, after incorporation in the OMM, only two amino-acids of the 
protein, 127 and the lysine 128, protrude in the IMS facing the IMM (Annis M.G. et al 2005). 
The fact that the lysine seem to be highly conserved among all pro-apoptotic members and 
excluded in the anti-apoptotic ones of the same family (Szabo I. et al 2011) led to the 
hypothesis that Bax (and Bak) induce apoptosis in a toxin-like manner. Studies on isolated 
Kv1.3-positive mitochondria incubated with recombinant Bax, t-Bid or Kv1.3-targeting toxins 
showed the induction of apoptotic events, whereas Kv1.3-deficient mitochondria were 
resistant to the same stimuli (Szabo I. et al 2008). Moreover, patch clamp and mutation 
analysis revealed a functional interaction between Kv1.3 and Bax upon apoptosis, which is 
strictly dependent on the presence of the positively charged lysine at position 128, since 
mutation of this residual into a negatively charged glutamate (Bax K128E), corresponding to 
K128 in Bax, abrogated the apoptotic effects. On the contrary, conversion of glutamate 158 
into lysine in the anti-apoptotic Bcl-xL (Bcl-xLE158K) restored these effects (Szabo I. et al 
2011). Transfection of Bax/Bak double knockout mouse embryonic fibroblasts cells (DKO 
MEFs) with wild-type Bax, Bax K128E or Bcl-xL E158 also confirmed the hypothesis, by 
showing that apoptosis affected Bax and Bcl-xL E158 transfected DKO cells, but not Bax 
K128E transfected ones.  
Bax-mediated inhibition of Kv1.3 was shown to induce hyperpolarization, formation of ROS, 
release of cytochrome c and marked depolarization of the mitochondrial membrane of Kv1.3-
positive mitochondria (Szabo I. et al 2008). These findings, confirmed also by the use of 
pharmacological inhibitors ShK, MgTx and Psora-4, led to hypothesize a model of action of 
mtKv1.3 in apoptosis (Figure 1.4). Particularly, Bax interaction with mtKv1.3, after ROS- or 
apoptotic stimuli-dependent translocation to the OMM, blocks the positive inward K
+
 flux, 
triggering an initial hyperpolarization of the mitochondrial membrane. Mitochondrial 
membrane hyperpolarization causes reduction of respiratory chain complexes, such as Fe/S 
centres, cytochrome c and ubiquinone pool, uncoupling the H
+
 gradient and causing an 
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increase of ROS production (Murphy M.P. 2009, O'Rourke B. et al 2005). ROS can activate 
the PTP through oxidation of cysteine residues, leading to depolarization of the mitochondrial 
membrane and release of mitochondrial proteins (Costantini P. et al 1996, Giorgio M. et al 
2005, Scorrano L. 2009, Zoratti M. et al 1995). ROS can also favor the detachment of 
cytochrome c from the cristae by changing the oxidation state of membrane lipids, such as 
cardiolipin, that bind to cytochrome c (Iverson S.L. et al 2004, Ott M. et al 2007), but other 
yet unknown mechanisms might also be important for this process. Cytochrome c is then 
released through OMM rupture and Bax oligomers triggering, once in the cytosol, the 
activation of the intrinsic apoptotic pathway. It has been demonstrated that Bax can also 
interact with other channels than Kv1.3, including Kv1.5 and Kv1.1 (Szabo I. et al 2011). 
Moreover, cytochrome c release has been shown to occur also through the interaction of Bax 
with big potassium (BK)-channels in the IMM, but whether the mechanism is similar to the 
Kv1.3-Bax interaction still has to be understood (Cheng Y. et al 2011). 
 
 
Figure 1.4. Model for the intrinsic apoptosis induction via mtKv1.3 inhibition. Membrane permeant Kv1.3 
inhibitors PAP-1, Psora-4 and clofazimine induce intrinsic apoptosis blocking the mtKv1.3 in a Bax-similar 
manner, triggering a hyperpolarization of the mitochondrial membrane and increase of ROS production. ROS 
can both activate the permeability transition pore (PTP), leading to depolarization of the mitochondrial 
membrane and release of mitochondrial proteins, and favor the detachment of cytochrome c from the cristae. 
Cytochrome c is then released through OMM ruptures or Bax oligomers triggering, once in the cytosol, the 
activation of the intrinsic apoptotic pathway (Leanza L. et al 2014b). 
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1.2.4 mtKv1.3 and cancer 
The crucial role of Kv channels in apoptosis and proliferation is underlined by their 
differential expression in various tumor cells (Arcangeli A. et al 2009). Particularly, changes 
in Kv1.3 expression have been detected in various cancers, including large B-cell lymphoma 
(Alizadeh A.A. et al 2000), melanoma (Artym V.V. et al 2002), glioma (Bielanska J. et al 
2009, Preussat K. et al 2003), prostate and pancreas (Abdul M. et al 2006), colon (Abdul M. 
et al 2002), breast (Jang S.H. et al 2009) and gastric cancer (Lan M. et al 2005). Moreover, 
Kv1.3 has been found in mitochondria of lymphoma and B-CLL leukemia, MEF cells, 
melanoma B16F10 and osteosarcoma SAOS-2 cells, prostate PC3 and breast cancer MCF-7 
cell lines (Gulbins E. et al 2010, Leanza L. et al 2013).  
Standing to this knowledge, the above mentioned model of Kv1.3 Bax-mediated inhibition 
was applied to induce apoptosis in different cancer cell lines, showing that the use of specific 
membrane-permeable inhibitors Psora-4, PAP-1 and clofazimine mimic the effects of Bax-
mtKv1.3 interaction. The inhibitors successfully induced apoptosis in Kv1.3-expressing 
Jurkat, B16F10 and SAOS-2 cancer cell lines, whereas cells displaying a low or absent Kv1.3 
current such as, respectively, HEK293 or K562 cells, failed to undergo apoptosis when treated 
with these inhibitors (Leanza L. et al 2013). Importantly, experiments with Bax/Bak-double 
knockout human (DKO) Jurkat leukemic T cells and Bax/Bak DKO MEFs demonstrated that 
these apoptotic effects are independent from the presence of the pro-apoptotic proteins Bax 
and Bak (Szabo I. et al 2011). In vivo, a B16F10 melanoma mouse model showed a 90% 
reduction when treated with the Kv1.3 inhibitor clofazimine. Moreover, primary human 
cancer B cells from patients with chronic lymphocytic leukemia (B-CLL) were shown to 
express a higher level of functional channel compared to B cells of healthy subjects. When 
treated with different Kv1.3 blockers, malignant cells underwent apoptosis, whereas healthy 
cells were spared (Leanza L. et al 2013). Interestingly, apoptosis-inducing effect of Kv1.3 
inhibitors were absent in pathologic B cells pretreated with ROS detoxifying enzymes, as well 
as in CTLL-2 cells exposed to oxidative stress. Conversely, pre-treatment with pro-oxidant 
agents alone was not able to induce cell death in healthy B cells, which encountered apoptosis 
only after addition of Kv1.3 inhibitors. These findings show a synergistic action of Kv1.3 
expression and altered redox state of malignant cells which contributes to the sensitivity to the 
drugs.
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1.3 Glioblastoma 
Glioblastoma (also called glioblastoma multiforme, GBM or grade IV Astrocytoma) is the 
most common and malignant tumor among glia neoplasms (Louis D.N. et al 2007). GBM is 
composed by a heterogeneous mixture of scarcely differentiated astrocytes and it usually 
localizes in the cerebrum, less frequently in the brain stem or in the spinal cord. It affects 
mostly but not only adults. Unlike other cancers and as all glial tumors, it does not expand out 
of the central nervous system by spreading through blood, but it invades the brain and spinal 
cord by active cell migration. GBM usually develops de novo (‘primary’ tumor) but can also 
arise from a fibrillary (or diffuse, grade II) astrocytoma or from an anaplastic astrocytoma 
(grade III), in that cases is called ‘secondary’ tumor (Ohgaki H. et al 2007). GBM current 
standard of care for newly diagnosed patients, established in 2005, consist of maximal 
surgical resection, followed by temozolomide (TMZ)-based chemotherapy in combination 
with radiation therapy (RT) (Stupp R. et al 2005). However, due to the high recurrent rates 
(~90%), patient average survival does not exceed 15 months after diagnosis (Johnson D.R. et 
al 2012). 
One of the major obstacles to the treatment is represented by the migratory invasive behavior 
of glioblastoma cells. Indeed, even if, especially in GBM, but also in the other brain tumors, 
the blood brain barrier (BBB) is altered, showing hypercellularity, pleomorphism, high 
mitoses, central necrosis and excessive vascularization (Wolburg H. et al 2012), the BBB 
breakage is highly heterogeneous, often presenting the tumor core much more permeable than 
the proliferating tumor periphery (Neuwelt E.A. et al 1982). Thus, although chemotherapeutic 
drugs can reach GBM, it is very difficult to act on single tumor cells in the infiltration zone 
where the BBB is less or not altered. On the other hand, the treatment of a high grade 
glioblastoma, easier to reach thanks to the higher permeability, but with necrotic center, 
results to be too tardive. 
1.3.1 GBM and K+ channels 
To control migration through the narrow extracellular spaces, glioma cells possess a devoted 
ion channel apparatus that finely regulates ion and water fluxes. Sontheimer’s laboratory 
highlighted an intricate network of ion channel expression studying both glioma cell lines and 
primary samples (Cuddapah V.A. et al 2011). Particularly, glioma cells seem to shrink their 
volume, thanks to K
+ 
channels which, together with Cl
-
 channels, promote cell shrinkage 
initiating an efflux of KCl. The main K
+
 channel expressed by gliomas is gBK, encoded by 
KCNMA1 or KCa1.1, a splice variant of the hslo BK channel gene (Liu X. et al 2002, Ransom 
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C.B. et al 2001), which is exclusively found in glioma. BK currents in glioma cells are more 
sensitive to cytosolic Ca
2+
 compared to BK channels of healthy glial cells (Ransom C.B. et al 
2002). Inhibitors of this channel potently block glioma cell invasion, in vitro and in situ. 
However, concentrations of inhibitors sufficient to block the channel do not affect 
glioblastoma growth in vitro (Abdullaev I.F. et al 2010). Biopsies from patients with 
malignant glioma showed an overexpression of BK channels compared to nonmalignant 
cortical tissues, and a positive correlation with tumor malignancy of BK channels expression 
was found (Liu X. et al 2002). Kv10.1, the Kv channel with the broader expression in 
different cancers, is expressed in neuroblastoma, and its targeted inhibition decreases cancer 
cell proliferation, also in human glioma cells (Jeon S.H. et al 2011, Pardo L.A. et al 2012). 
Glioma cells show, both in vitro and in situ, a depolarized resting membrane potential (-20 to 
-40 mV) (Bordey A. et al 1998)compared to the very negative one of normal glial cells (-80 to 
-90 mV) (Newman E.A. 1993), which is proposed to be due to intracellular 
localization/mislocalization of inwardly rectifying (Kir) channels, since no significant 
downregulation of Kir channels was found (Olsen M.L. et al 2004). Furthermore, in glioma, 
hERG (or Kv11.1, hERG1) channel current seems to substitute the IRK (Kir, inwardly 
rectifying channels) expression normally found in glial cells, thus also suggesting a 
contribution to cell depolarization typical of neoplastic transformation (Bianchi L. et al 1998). 
Regarding Kv1.3, this channel was shown to be expressed in neuroblastomas (Friederich P. et 
al 2002). Preussat and colleagues have previously shown that voltage gated channel subtypes 
Kv1.3, together with Kv1.5, contribute to growth related properties of normal glia, and that 
Kv1.5 expression correlated with glioma entities and malignancy grade (Preussat K. et al 
2003). Such correlation was not found for Kv1.3 expression. Also, another work from Bonnet 
et al. demonstrated an apoptosis inducing effect after the normalization of a mitochondria-K
+
 
channel axis by the Kv1.5-upregulating drug dichloroacetate (DCA) on a glioma cell line 
(Bonnet S. et al 2007). Particularly, it has been shown that is possible to induce cell death in 
different glioma cell lines expressing low level of Kv1.5. The same group already used DCA 
in patients with promising results in a small study (Michelakis E.D. et al 2010). 
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1.4 Aims of the study 
The groups of Prof.s Szabò and Gulbins demonstrated that the inhibition of the mtKv1.3 by 
different membrane-permeant specific drugs is able to induce apoptosis in different cancer 
cell lines in vitro, ex vivo in B-CLL cells and in a in vivo orthotopic mouse melanoma model 
(Leanza L. et al 2012, Leanza L. et al 2013). 
Here, I tested different Kv1.3 inhibitors on their ability to influence tumor growth in two 
types of models, glioma and melanoma. In particular, I investigated whether these drugs are 
able to induce cell death by depolarizing the mitochondrial membrane, increasing ROS 
production, eventually leading to cytochrome c release in different cancer cell lines.  
Thanks to their augmented solubility and mitochondrial targeting ability, the newly 
synthesized drugs, together with clofazimine, were applied, after a pharmacokinetic analysis, 
in vivo to a syngeneic glioma model and to the orthotopic melanoma model. Beside the 
impact on tumor growth, the synergistic effect with ROS level, previously proposed in the in 
vitro studies, was analyzed. 
The last part of the study focused on the mechanism of the in vivo action of the precursor and 
the derivatives in the reduction of melanoma tumor, addressing the influence of these 
compounds on the immune system. Specifically, an analysis of the response of different 
immune cell subtypes (macrophages, T and B lymphocytes, regulatory T cells, neutrophils) to 
Kv1.3 inhibitors was performed. 
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2 MATERIALS 
2.1 Chemicals 
 
Acetic acid (C2H4O2) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Acetone 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Acetonitrile (CH3CN) Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Acrylamide Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Ammonium persulfate (APS) Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Aprotinin Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Aqua ad iniectabilia  
 
B. Braun Melsungen AG, Melsungen, 
Germany 
Atipamezole (Antisedan) 
 
Orion Pharma, Espoo, Finland 
 
Bovine serum albumin (BSA) Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Bromophenol blue Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Calcium chloride (CaCl2) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
CDP Star reagent Perkin Elmer, Waltham, MA, USA 
 
Cell dissociation buffer enzyme-free, PBS 
 
Life Technologies GmbH, Darmstadt, 
Germany 
Cell Titer96 AQueous One Solution Cell 
Proliferation assay 
 
Promega GmbH, Mannheim, Germany 
 
Cisplatin 
 
Teva GmbH, Ulm, Germany 
Clofazimine Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Dabco 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Dimethyl sulfoxide (DMSO) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Dithiothreitol (DTT) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
DNAse 
 
Roche Molecular Biochemicals, Penzberg, 
Germany 
EDTA 
 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
EGTA Carl Roth GmbH & Co. KG, Karlsruhe, 
MATERIALS 
19 
 Germany 
Eosin 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Ethanol (C2H5OH) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Ethidium bromide 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Fentanyl 
 
Rotexmedica GmbH Arzneimittelwerk, 
Trittau, Germany 
Flumazenil 
 
Hameln pharma plus GmbH, Hameln, 
Germany 
Gelatin 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Glycerol 
 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Glycine Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Hematoxylin solution, Mayer´s 
 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Heparin 
 
Ratiopharm GmbH, Ulm, Germany 
HEPES Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Leupeptin Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Magnesium chloride (MgCl2) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Magnesium sulfate (MgSO4) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Medetomidin Domitor 
 
Orion Pharma, Espoo, Finland 
 
2-Mercaptoethanol 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Methanol (CH3OH) (Baker) 
 
Avantor Performance Materials, Center 
Valley, PA, USA 
5-Methoxypsoralen (5-MOP) 
 
Synthesized by the Department of Chemical 
Sciences, University of Padua, Italy 
Midazolam  
 
Ratiopharm GmbH, Ulm, Germany 
Milk powder 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Mowiol Kuraray Europe GmbH, Hattersheim am 
Main, Germany 
N-acetylcysteine 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Naloxone 
 
Inresa Arzneimittel GmbH, Freiburg, 
Germany 
NP-40 (Igepal) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Paraformaldehyde (PFA) Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Paraplast plus Leica Microsystem,  Mannheim, Germany 
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Percoll  
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
5-(4-Phenoxybutoxy) psoralen (PAP-1) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Potassium chloride (KCl) 
 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Potassium dihydrogen phosphate 
(KH2PO4) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Protease inhibitors (tablets) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Proteinase K 
 
Qiagen, Hilden, Germany 
Psora-4 Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Sodium bicarbonate (NaHCO3) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Sodium carbonate (Na2CO3) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Sodium chloride (NaCl) 
 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium citrate 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Sodium dodecyl sulphate (SDS) Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium hydroxide (NaOH) 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Sodium phosphate dibasic (Na2HPO4) Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Staurosporine Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Sucrose  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
SuperSignal West Pico Chemiluminescent 
Substrate 
 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
TES 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Tris Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Triton X-100 Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Trypan blue solution 0.4 % Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Tween 20  Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Urea 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Xylene cyanol 
 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
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2.2 Tissue culture 
 
Dulbecco’s modified eagle medium 
(DMEM) – 31053 
 
Gibco/Invitrogen, Karlsruhe, Germany 
Dulbecco’s modified eagle medium 
(DMEM) - 41965  
 
Gibco/Invitrogen, Karlsruhe, Germany 
Minimum Essential Medium (MEM) -
21090 
 
Gibco/Invitrogen, Karlsruhe, Germany 
Opti-MEM 
  
Gibco/Invitrogen, Karlsruhe, Germany 
RPMI-1640 
 
Gibco/Invitrogen, Karlsruhe, Germany 
L-Glutamine 
 
Gibco/Invitrogen, Karlsruhe, Germany 
Sodium pyruvate 
 
Gibco/Invitrogen, Karlsruhe, Germany 
Penicillin/Streptomycin 
 
Gibco/Invitrogen, Karlsruhe, Germany 
MEM non-essential aminoacids 
 
Gibco/Invitrogen, Karlsruhe, Germany 
Fetal Calf Serum 
 
Gibco/Invitrogen, Karlsruhe, Germany 
2.5 % Trypsin 
 
Gibco/Invitrogen, Karlsruhe, Germany 
0.05 % Trypsin-EDTA Gibco/Invitrogen, Karlsruhe, Germany 
 
2.3. Antibodies and ligands 
 
AllStars negative control siRNA-Alexa 555 Qiagen, Hilden, Germany 
 
Annexin-V-FLUOS 
 
Roche Molecular Biochemicals, Penzberg, 
Germany 
Anti-Bax 
 
Santa Cruz Biotechnology, Inc., Delaware 
Ave, CA, USA 
Anti-CD3-PE  
 
BD Pharmigen, San Diego, CA, USA 
Anti-CD4-FITC  
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-CD8-APC  
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-CD11b-bio 
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-CD11c-Alexa 488 
 
Affymetrix eBioscience, San Diego, CA, 
USA 
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Anti-CD19-PE  
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-CD25-bio 
 
Becton Dickinson Labware, Le Pont de 
Claix, France 
Anti-CD204-APC  
 
BioRad, München, Germany 
Anti-cytochrome c 
 
BD Pharmigen, San Diego, CA, USA 
Anti-F4/80-Alexa 488 
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-FoxP3-PE 
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-GADPH 
 
EMD Millipore, MA, USA 
Anti-KCNA3 siRNA-Alexa 555 Qiagen, Hilden, Germany 
 
Anti-Kv1.3 
 
Alomone Labs, Jerusalem, Israel 
(Neuromab) Antibodies Inc., Davis, CA, 
USA 
Pineda 
„home made“ (affinity purified) 
 
Anti-Kv1.3-FITC 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Anti-Ly6G-APC  
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-MHCII-APC 
 
Affymetrix eBioscience, San Diego, CA, 
USA 
Anti-mouse IgG-AP 
 
Santa Cruz Biotechnology, CA, USA 
Anti-mouse IgG-HRP 
 
Santa Cruz Biotechnology, CA, USA 
Anti-rabbit IgG-AP 
 
Santa Cruz Biotechnology, CA, USA 
Anti-rabbit IgG-HRP 
 
Santa Cruz Biotechnology, CA, USA 
Anti-streptavidin-APC 
 
BD Pharmigen, San Diego, CA, USA 
Anti-streptavidin-PE 
 
BD Pharmigen, San Diego, CA, USA 
Anti-Tim23 
 
BD Pharmigen, San Diego, CA, USA 
Anti-Tom20 
 
BD Pharmigen, San Diego, CA, USA 
Anti-tubulin alpha 
 
Epitomics, Burlingame, CA, USA 
Cy3-anti mouse IgG 
 
Jackson Immunoresearch, West Grove, PA, 
USA 
Cy3-anti rabbit IgG Jackson Immunoresearch, West Grove, PA, 
USA 
Dylight-649 anti mouse IgG 
 
Jackson Immunoresearch, West Grove, PA, 
USA 
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FoxP3 intracellular staining 005523 Affymetrix eBioscience, San Diego, CA, 
USA 
 
In situ cell death detection kit, TMR red 
dUTP 
 
Roche Molecular Biochemicals, Penzberg, 
Germany 
Lipofectamine 2000  Life Technologies GmbH, Darmstadt, 
Germany 
MitoSOX Red Mitochondrial Superoxide 
Indicator 
 
Life Technologies GmbH, Darmstadt, 
Germany 
Tetramethylrhodamine, methyl ester 
(TMRM) 
 
Life Technologies GmbH, Darmstadt, 
Germany 
 
2.3 Cell lines 
 
A172 (ATCC CRL 1620) Established human glioblastoma cell line. 
Kind gift from Prof. Dr. M. Weller 
(University of Zürich)  
B16F10 (ATCC CRL 6475) 
 
Established murine melanoma cell line 
 
GL261 
 
Established mouse glioma cell line. Kind gift 
from Prof. Dr. M. Weller (University of 
Zürich) 
Jurkat (ATCC TIB 152) 
 
Established human T-lymphocytes cell line 
 
K562 (ATCC CCL 243) 
 
Established human myelogenous leukemia 
cell line 
LN308 
 
Established human glioblastoma cell line. 
Kind gift from Prof. Dr. M. Weller 
(University of Zürich) 
 
2.4 Equipment 
 
BD FACSCalibur flow cytometer  
 
BD Biosciences, San Jose, CA, USA 
Caliper 
 
Mitutoyo GmbH, Neuss, Germany 
Cell culture incubator  
 
ThermoFisher Scientific, Waltham, MA, 
USA 
Cell culture flask Corning Inc., NY, USA 
 
Cell culture, 6, 24 and 96 well plate Corning Inc., NY, USA 
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Cell scraper, 24 cm TPP, Trasadingen, Switzerland 
 
Cell strainer, 40 µm Becton Dickinson Labware, Le Pont de 
Claix, France 
Cryo 1C Freezing container  
 
Nalgene, USA 
Cryotubes 
 
ThermoFisher Scientific, Waltham, MA, 
USA 
Embedding cassettes 
 
Fisher Scientific, The Hague, The 
Netherlands 
FACS polystyrene round-bottom tubes 
 
Becton Dickinson Labware, Le Pont de 
Claix, France 
Glass pestle (Glas Col) ABCR GmbH & Co. KG, Karlsruhe, 
Germany 
 
HPLC machine 
 
Agilent Technologies Inc., Santa Clara, CA, 
USA 
HPLC column  
 
Agilent Technologies Inc., Santa Clara, CA, 
USA 
Hybond ECL nitrocellulose membrane 
 
GE Healthcare, USA 
Interlocked vial with fused glass insert, 
screw top 
 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Laminar flow hood 
 
Biohit/Sartorius Antares, Milano, Italy 
Leica DMI-4000 fluorescence microscope 
 
Leica Microsystem,  Mannheim, Germany 
Leica TCS SP5 confocal microscope 
 
Leica Microsystem,  Mannheim, Germany 
Micro fine U-40 insulin syringes 29G Becton Dickinson Labware, Le Pont de 
Claix, France 
Microliter syringe  Zefa-Laborservice GmbH, Harthausen, 
Germany 
Microscope slide 76x26 mm Gerhard Menzel GmbH, Braunschweig, 
Germany 
Microtome  
 
ThermoFisher Scientific, Waltham, MA, 
USA 
Neubauer chamber 0.1 mm Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany 
Packard Spectracount absorbance 
microplate reader 
 
Cole Parmer, East Bunker Court Vernon 
Hills, IL, USA 
Pellet pestles blue polypropylene Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Pellet pestles cordless motor Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Polyvinylidene fluoride membrane (PVDF) Pall Corporation, Pensacola, USA 
 
Precision Drill 
 
Proxxon, Niersbach, Germany 
Scalpels, sterile disposable Servoprax GmbH, Wesel, Germany 
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Screw cap (open top) with liner Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Spectrophotometer 
 
Bachofer, Reutlingen, Germany 
SpeedVac 
 
ThermoFisher Scientific, Waltham, MA, 
USA 
Stereotaxic instrument 
 
TSE Systems GmbH, Bad Homburg, 
Germany 
X-ray films  Amersham Biosciences, Buckinghamshire, 
UK 
  
2.5 Buffers and solutions 
 
Agarose gel (0.8%) 0.8 g agarose 
100 ml TAE buffer 
 
Alcaline phosphatase wash buffer 
 
100 mM Tris/HCl pH 9.5 
100 mM NaCl 
 
Annexin-binding buffer 10 mM Hepes pH 7.4 
140 mM NaCl 
5 mM CaCl2 
 
Cell membrane enrichment lysis buffer 5 mM Tris/HCl pH 7.5 
0.25 % Triton X100 
1 mM EDTA 
1 mM DTT 
Protease inhibitors 
0.2 M NaCl 
 
Complete DMEM, MEM, Optimem or 
RPMI 
500 ml DMEM, MEM, Optimem or RPMI 
10% FCS 
10 mM Hepes pH 7.4 
2 mM L-Glutamine 
1 mM Sodium pyruvate 
100 µM non-essential amino acids 
100 U/ml penicillin 
100 µg/ml streptomycin 
 
Hepes/Saline (H/S) 20 mM Hepes pH 7.4 
132 mM NaCl 
1 mM CaCl2 
0.7 mM MgCl2 
0.8 mM MgSO4 
5.4 mM KCl 
 
Mowiol 
 
2.5 g Mowiol 
2.5 % Dabco 
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Percoll gradient 
 
 
60 % Percoll (in TES buffer) 
30 % Percoll (in TES buffer) 
18 % Percoll (in TES buffer) 
 
PFA stock solution 
 
8% PFA 
in PBS 
 
Phosphate buffered saline (PBS), pH 7.4 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
 
PBS-T 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
0.05 % Tween 20 
 
PCR-buffer (10X) 
 
200 mM Tris-HCl pH 8.3 
500 mM KCl 
14 mM MgCl2 
0.1 % Gelatin 
 
Running buffer 25 mM Tris 
192 mM glycine 
0.1 % SDS 
 
Sample buffer (5X) 250 mM Tris pH 6.8 
20 % Glycine 
4 % SDS 
8 % β-mercaptoethanol 
0.2 % bromophenol blue 
 
TAE buffer (50X) 
 
2 M Tris 
1 M Acetic acid 
0.05 M EDTA pH 8 
 
TBS, pH 7.4 20 mM Tris 
150 mM NaCl 
 
TBS-T 20 mM Tris 
150 mM NaCl 
0.05 % Tween 20 
 
TES buffer 300 mM Sucrose 
10 mM TES pH 7.4 (KOH) 
1 mM EGTA pH 7.4 (KOH) 
Protease inhibitors 
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TLB buffer 
 
0.5 mM MgCl2 
10 % 10X PCR-Buffer 
0.045 % Tween 20 
0.045 % NP-40 (Igepal) 
300 µg/ml Proteinase K 
 
Transfer buffer (for nitrocellulose) 
 
25 mM Tris 
192 mM glycine 
10 % Methanol 
 
Transfer buffer (for PVDF) 10 mM NaHCO3 
3 mM Na2CO3 
10 % Methanol 
 
Trypsin (0.25%) pH 7.4 10X Trypsin (2.5%) 
0.05 % EDTA 
5 mM Glucose 
10X PBS 
 
2.6 Animals 
Mice were bred and housed in a special pathogen free facility at the University of Duisburg-
Essen, with 12h light/dark cycle at constant temperature and humidity, allowed daily food and 
water ad libitum. All experiments were funded by G1093/09 grant and approved by the 
Animal Care and Use Committee of the Bezirksregierung Düsseldorf, Düsseldorf, Germany.  
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3 METHODS 
3.1 Cell culture techniques 
3.1.1 Culture and passage of established cell lines 
Jurkat and K562 cell lines were maintained in complete RPMI medium (see Materials); 
B16F10 cells were maintained in complete MEM medium at 37°C in a 5% CO2 atmosphere. 
GL261, A172 and LN308 cells were cultured in complete DMEM medium at 37°C with 10% 
CO2. For passage, adherent cells were washed once with PBS, incubated with 0.25% trypsin 
(or 0.05% Trypsin-EDTA for GL261 cells) for 5 min at 37°C and re-suspended in fresh 
medium. All cells were maintained at a sub-confluent state, which was ordinarily assessed by 
light microscopy. All cell lines were tested monthly by PCR to exclude mycoplasma 
contaminations. 
3.1.2 Freezing and thawing of cells 
Cells were frozen after centrifugation at 400 x g for 10 min at RT and re-suspending the cell 
pellet in complete medium supplemented with 10% FCS and 10% DMSO. 1 ml aliquots were 
transferred to cryotubes and frozen in a freezing container at -80°C. After 2-3 days, cryotubes 
were placed in liquid nitrogen for long-term storage. Cells were thawed in a water bath at 
37°C and immediately transferred in a T25 flask containing complete medium and let grow 
O/N at 37°C. Medium was then replaced and cells eventually transferred to a T75 flask. 
3.2 PAP-1 derivatives  
PAP-1 derivatives PEGME, PCARBMTP and PAPTP were synthesized by the Department of 
Chemical Sciences of the University of Padua (Italy) as described in the patent license 
number PD2015A000006. For treatments, all derivatives were dissolved in DMSO while, in 
all cases, the final concentration of DMSO was lower than 0.5%. 
3.3 Cell viability assay 
3.3.1 Trypan blue 
To assess cell viability, 5 x 10
4
 cells per well were seeded in a 12 well plate in 1 ml complete 
medium over-night (O/N). After treatment with compounds, supernatant were collected and 
cells were trypsinized for 5 min at 37°C. Supernatants were added to the cells and centrifuged 
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at 500 x g for 5 min at RT. Cells were then re-suspended in 100 µl PBS and 50 µl of this 
suspension were added to 50 µl 0.4% Trypan blue solution. After 3-5 min incubation at RT, 
10 µl were analyzed in a Neubauer chamber. Viable and non-viable cells were counted by 
light microscopy.  
3.3.2 MTT assay 
To assess cell survival, colorimetric MTT assay was used. The assay exploits the activity of 
the mitochondrial dehydrogenases, which, if active, reduce the yellow tetrazolium salt MTT 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide to a purple insoluble 
compound, the formazan. Absorbance values are proportional to the amount of produced 
formazan and thus, to the metabolic activity of the cells. 0.005 x 10
6
 cells/ well were seeded 
in a 96 well plate O/N and treated with different compounds or left untreated in DMEM w/o 
phenol red and w/o FCS. According to the manufacturer’s protocol, 20 µl Cell Titer 96 
AQUEOUS One Solution were added to each well and incubated between 2-3 h at 37°C in the 
dark. Absorbance was read at 490 nm by spectrophotometry.  
3.4 Biochemical techniques 
3.4.1 Cell membrane fraction enrichment 
Channels are present in membranes in much lower concentration compared to soluble 
proteins, therefore they are slightly detectable in a whole cell total extract. To improve 
channel detection, a cell membrane enrichment protocol was used. 0.8 x 10
6
 adherent cells 
were seeded in a 100 mm tissue culture dish O/N. The day after, adherent cells were washed 
once in 0.9% NaCl, scraped in 285 µl ice cold lysis-buffer and transferred to a 1.5 ml tube on 
ice. For suspension cells, 1.5 x 10
6
 cells were collected at 400 x g for 5 min at RT and re-
suspended in the same volume of lysis buffer. All cells were vortexed 50 sec, then 15 µl of 4 
M NaCl were added and vortexed for further 15 sec. Broken cells were centrifuged at 20000 x 
g for 10 min at 4°C. The resulting pellet (cell membrane fraction) was re-suspended in 100 µl 
lysis buffer and stored at -80°C. 
3.4.2 Mitochondria isolation 
Approximately 2 x 10
8
 cells were washed twice with 10 ml PBS and scraped in 2-3 ml PBS. 
Cells were collected and washed two times in 40 ml PBS at 500 x g for 10 min at RT. Each 
pellet was re-suspended in 1 ml ice cold TES buffer and dounce homogenized 75 times in a 
glass pestle (tight) after assessing the degree of rupture by Trypan blue. From this 
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homogenate, 200 µl were rescued as fraction 1 (total lysate). The remaining lysate was 
divided in 4 parts and centrifuged at 600 x g for 10 min at 4°C to pellet unbroken cells. 
Supernatants were collected, while pellets were re-suspended in 500 µl TES buffer and 
dounce homogenized for further 75 times. The lysate was centrifuged as described above and 
the resulting supernatant was added to the previous one. Supernatants were centrifuged at 800 
x g for 10 min at 4°C to remove remaining unbroken cells. Supernatants were collected and 
centrifuged at 8000 x g for 10 min at 4°C to pellet organelles, among which mitochondria. 
Pellets were re-suspended in a total volume of 800 µl TES buffer and 200 µl of this 
suspension was rescued as fraction 4. The remaining 600 µl were carefully added on the top 
of Percoll gradients and centrifuged at 8500 x g for 10 min at 4°C with soft brake. 500 µl 
were rescued from each M1 fraction (isolated mitochondria, between 18% and 30% Percoll 
phases) and washed three times with 1.5 ml TES buffer at 20000 x g for 10 min at 4°C to 
eliminate Percoll. The obtained pellet (mitochondria) was re-suspended in 40 µl TES buffer 
and stored at -80°C. 
3.4.3 Cytochrome c release assay 
To detect the release of cytochrome c, 0.2 x 10
6
 cells / well were seeded in a 6 wells plate 
O/N and either treated with different compounds or left untreated. Medium was then removed 
and centrifuged at 1000 x g for 5 min at 4°C, to collect detached cells. In the meanwhile, cells 
of each well were gently washed once with PBS, scraped in 200 µl ice cold TES buffer per 
well and immediately collected in a 1.5 ml tube. Pelleted cells were added to the cells by 
resuspending it in the same TES buffer. After 30 min incubation on ice, cells were broken 
with a pellet pestle for 1 min and 15 sec on ice, according to the rupture test previously done 
with Trypan blue. The lysate was then centrifuged at 19000 x g for 10 min at 4°C. The 
supernatant (cytosolic fraction) was collected and the pellet (mitochondrial fraction) was re-
suspended in 50 µl TES buffer. Both cytosolic and mitochondrial fractions were stored at -
80°C. 
3.4.4 Protein separation by SDS-PAGE 
Proteins were analyzed by using SDS-PAGE technique (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis). Prior to loading, samples were solubilized in 5-fold 
sample buffer for 5 min at 96°C, except where differently specified. Equal amounts of 
material were loaded in a 10% or 12% acrylamide gel (prepared as described below): 
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Running gel (without urea) 10%: 
Solution A 3.75 ml 
Solution B 5.0 ml 
H2O 6.11 ml 
SDS 20 % 0.075 ml 
TEMED 0.03 ml 
APS 10 % 0.03 ml 
 
Stacking gel: 
Solution A 0.63 ml 
Solution C 0.21 ml 
H2O 4.1 ml 
SDS 20 % 0.025 ml 
TEMED 0.02 ml 
APS 10 % 0.02 ml 
 
Running gel (with urea) 10%: 
Urea 3.63 g 
H2O 2.09 ml 
Solution B 2.67 ml 
Solution A 2.5 ml 
TEMED 0.0055 ml 
APS 10 % 0.055 ml 
 
Running gel 12%: 
Solution A 3 ml 
Solution B 1.24 ml 
H2O 5.66 ml 
SDS 10 % 0.1 ml 
TEMED 0.02 ml 
APS 10 % 0.03 ml 
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Stacking gel: 
Solution A 0.373 ml 
Tris 0.313 M pH 6.8 1 ml 
H2O  1.62 ml 
TEMED 0.0035 ml 
APS 10 % 0.035 ml 
 
Solution A: 40 % Acrylamide (39.2 g Acrylamide/ 100 ml; 0.8 g Bis-acrylamide/ 100 ml) 
Solution B: 3 M Tris pH 8.8 
Solution C: 3 M Tris pH 6.8 
 
10% and 12% gels were run at 15 mA (stacking gel) and 50 mA (running gel). Samples were 
transferred by tank blotting method from the gel to either a nitrocellulose or PVDF 
membrane, at 25 mA or 40 V, respectively, O/N at 4°C. The transfer buffer was prepared as 
written in the Materials. Nitrocellulose or PVDF membranes were then washed once in PBS 
(or TBS for PVDF) for 10 min and blocked in 4% BSA (in PBS) or 10% milk (in TBS), 
respectively, for 1h at RT. Membranes were washed again in PBS (or TBS) for 10 min and 
incubated with the primary antibody for 1h at RT or O/N at 4°C. Nitrocellulose and PVDF 
membranes were washed in PBS-T (6 x 5 min) or TBS-T (3 x 10 min) respectively, and 
incubated with the secondary antibody (alkaline phosphatase or horseradish peroxidase-
conjugated) for 1h at RT. Membranes were then washed as above; PVDF membranes were 
additionally washed with alkaline-phosphatase wash buffer for 5 min. Membranes were then 
incubated with CDP-Star or SuperSignal West Pico Chemiluminescent substrates, 
respectively, for 5 min at RT. Radiation was detected after several minutes exposure to an X-
ray film in the dark. When needed, nitrocellulose or PVDF membranes were stripped for 10 
min in 0.2 M NaOH or for 1h in Stripping solution, respectively, then blocked and re-
incubated with another primary antibody. Quantification was performed by using Multi 
Gauge 3.0 software. 
3.4.5 High pressure liquid chromatography (HPLC) analysis 
a) Sample preparation 
Mice were sacrificed at the desired time point and 50 µl blood were immediately collected 
from the heart and transferred in a 1.5 ml tube with 30 µl heparin (Cst: 25000 U/ml). To obtain 
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plasma, blood was centrifuged at 400 x g for 10 min at 4°C and the resulting supernatant was 
carefully collected. Blood was treated within 10 min from collection as described below. 60 
µl were taken from the tube and supplemented with the following compounds: 
 1/10 vol acetic acid 4.35 M 
 1/10 vol 5-MOP 100 µM (in acetone)  
 10 volumes acetone 
Samples were mixed by inversion 20 times, sonicated for 2 min and centrifuged at 12000 x g 
for 7 min at 4°C. Then, 600 µl of the supernatant were collected and stored at -20°C. 
Maximum 150 mg of the other organs were removed from the mouse, put in a 2 ml tube and 
weighted. 1 volume of cold PBS was added and organs were homogenized with an electronic 
pestle. Before the homogenization, organs (except brains) were cut in small pieces. Samples 
were then vortexed for 2 min and the same amounts of compounds written above for blood 
were added (volumes referred to the initial volume of the organ). Samples were then 
processed as written for blood and eventually 600 µl of supernatant was stored at -20°C. All 
organs were concentrated in the SpeedVac until 50-100 µl of the initial volume was left. 
Samples were then re-suspended in 40-60 µl acetone (20 µl step-wise, mixing) and 
centrifuged at 12000 x g for 5 min at 4°C to precipitate proteins. An accurately measured 
portion of supernatant was collected and stored at -80°C for further HPLC analysis. 
b) Calibration/ standard curves 
Standard solutions of clofazimine, PAPTP, PAP-1, PCARBMTP and PEGME in acetonitrile 
(in the concentration range of 0.1-20 µM) were analyzed by HPLC/UV as described below; 
peak area at the maximum absorption wavelength (286 nm for clofazimine and 320 nm for 
PAP-1 and its derivatives) was plotted against concentration to determine the correlation 
between peak area and amount analyzed.  
c) HPLC analysis 
2 µl samples were analyzed by HPLC/UV (1290 Infinity LC System, Agilent Technologies) 
using a reverse phase column (ZORBAX Extend-C18, 3.0 x 50 mm, 1.8 µm, Agilent 
Technologies) and a UV diode array detector (190-500 nm). Water containing solvents A and 
B were 0.1 % TFA and acetonitrile, respectively. The gradient for B for clofazimine, PAP-1 
and derivatives was as follows: 10% for 0.5 min, from 10% to 100% in 4.5 min, 100% for 1 
min; 0.6 ml/min flow rate. The eluate was preferentially detected at 286, 310 and 320 nm 
(corresponding to absorbance of clofazimine, internal standard and PAP-1 and its derivatives, 
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respectively). The temperature of the column was kept at 35°C. I established the procedure in 
Padua (Italy) and later sent the samples, prepared as described in a), to be analyzed. 
d) Recovery yields 
To establish the recovery yields of clofazimine and PAP-1 derivatives from blood and organs, 
the sample preparation protocols for blood or tissues were applied to samples spiked with a 
known amount of clofazimine or PAP-1 derivative. 1 ml blood from untreated animal was 
spiked with 5 nmoles clofazimine or PAP-1 derivative (dilution from a 1000x stock solution 
in DMSO). 100 µl aliquots were then taken and processed as described above. 1 g of tissue 
from untreated animal was mixed with 1 ml PBS containing 5 nmoles clofazimine or PAP-1 
derivative (dilution from a 100X stock solution in DMSO), and homogenized. 200 mg 
aliquots of the homogenate were taken and processed as mentioned above. Recoveries of 
clofazimine, PAP-1, PAP-1 derivatives and internal standard were determined by the 
Department of Biomedical Sciences in Padua (Italy) as described in (Azzolini M. et al 2014). 
3.5 Cytometry techniques 
3.5.1 Surface staining of cells 
1 x 10
6
 cells were collected at 500 x g for 10 min at RT. Cells were then re-suspended in 1µg 
of FITC labeled anti-Kv1.3 antibody in 50 µl DMEM w/o phenol red and w/o FCS for 1h in 
ice at 4°C. After adding 350 µl of DMEM w/o phenol red and w/o FCS to the cells, Kv1.3 
signal was detected at the FACS. FITC was excited with a 488-nm laser and detected at 525 
nm in the FL1 channel using a BD CellQuest Pro software. 
3.5.2 Detection of apoptosis by FITC-Annexin V staining 
To detect apoptosis induced by different inhibitors, 5 x 10
4
 cells per well were seeded in a 12 
well plate O/N at 37°C. The next day, cells were either treated with different compounds or 
left untreated. At the desired time points, supernatant were collected and cells were 
trypsinized after gently washing once in PBS. Trypsinized cells were collected in 1 ml 
medium and added to the supernatants, centrifuged at 500 x g for 5 min at 4°C and washed 
once in 1 ml Annexin V wash buffer as above. Pellets were then incubated with FITC-
Annexin V FLUOS (1:100 in Annexin V wash buffer) for 15 min at RT in the dark. 200 µl 
Annexin V wash buffer were added, the samples transferred to FACS tubes and analyzed at 
the FACS Calibur. FITC was excited by using a 488-nm laser and detected at 525 nm (FL1) 
through a BD CellQuest Pro software. 
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3.5.3 Analysis of tumor immune cells 
After 10 days from tumor cells injection, mice were treated once with different membrane 
permeant Kv1.3 inhibitors or their derivatives and then sacrificed after 24h. Tumors were 
removed from the flank and meshed with the plunger of a 5 ml syringe in 1 ml cold PBS in a 
12 well plate. After filtering with a 40 µm strainer and washing with an additional 1 ml PBS, 
cells were counted and 1 x 10
6
 cells were collected at 500 x g for 5 min at 4°C. After blocking 
in 0.05 ml True Stain Fc (1:100 in PBS) for 15 min at 4°C, 0.05 ml of an antibody mix 
(prepared 2X, in PBS) was added to the samples with the same conditions. After washing in 1 
ml PBS at 500 x g for 5 min at 4°C, samples were analyzed at the FACS. Biotinylated 
antibodies were further incubated with streptavidin-conjugated fluorescence labeled 
antibodies for 10 min at 4°C, washed and analyzed at the FACS after re-suspension in 0.05 ml 
PBS. For FoxP3 detection, after incubation with antibodies against surface markers, cells 
were fixed and permeabilized with the FoxP3 Intracellular Staining kit as described in the 
manufacturer’s protocol. Briefly, cells were incubated in 1 ml Fixation/Permeabilization 
solution for 30 min at 4°C, then collected at 500 x g for 5 min at 4°C and washed twice in 0.5 
ml Permeabilization buffer as described above. After incubation with the FoxP3 antibody (in 
Permeabilization buffer) for 30 min at 4°C, cells were washed twice in 0.5 ml 
Permeabilization buffer at 500 x g for 5 min at 4°C, re-suspended in 0.05 ml PBS and 
analyzed at the FACS using a BD CellQuest Pro software. FITC-coupled antibodies were 
excited with a 488-nm laser and detected at 525 nm (FL1). Alexa Fluor-488 coupled 
antibodies were excited with a 488-nm laser and detected at 519 nm (FL1). PE-coupled 
antibodies were excited at 488 nm and detected at 575 nm (FL2). APC-coupled antibodies 
were excited with a 633-nm laser and detected at 660 nm (FL4).  
Antibody dilutions (2X): 
Anti-CD3-PE  
 
1:500 
Anti-CD4-FITC  
 
1:1000 
Anti-CD8-APC  
 
1:500 
Anti-CD11b-bio 
 
1:2000 
Anti-CD11c-Alexa 488 
 
1:1000 
Anti-CD19-PE  
 
1:1000 
Anti-CD25-bio 
 
1:1000 
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Anti-CD204-APC  
 
1:10 
Anti-F4/80-Alexa 488 
 
1:500 
Anti-FoxP3-PE 
 
1:400 
Anti-Ly6G-APC  
 
1:750 
Anti-MHCII-APC 
 
1:500 
Anti-streptavidin-APC 
 
1:1000 
Anti-streptavidin-PE 
 
1:4000 
 
3.6 Histology techniques  
3.6.1 Paraffin embedding of organs 
Untreated or treated mice were sacrificed, organs removed and put in an embedding cassette 
in 4% PFA (in PBS) for 36h at RT, kindly shaking. After briefly washing in flowing H2O, 
samples were dehydrated as described below: 
50 % EtOH 2h 
60 % EtOH 2h 
70 % EtOH 2 x O/N 
96 % EtOH 2 x 4h 
100 % EtOH 2 x 4h 
100 % EtOH O/N 
Paraplast plus I 4h at 60°C 
Paraplast plus II O/N at 60°C 
Paraplast plus  III 4h at 60°C 
 
Samples were then embedded in fresh paraffin and sectioned with the microtome 
(ThermoFisher Scientific) at a thickness of 6 µm. 
3.6.2 Haematoxylin-eosin staining 
Samples were processed as described below.  
 Rehydration 
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3 x 15 min Xylol 
2 x 5 min 100 % Ethanol 
2 x 5 min  96 % Ethanol 
2 x 5 min 90 % Ethanol 
1 x 5 min  70 % Ethanol 
2 x 2 min  Millipore 
 
 Hematoxylin staining 
1 x 5 min Hematoxylin solution, Mayer 
8 min Flowing water 
 
 Eosin staining 
1 x 2 min  Eosin (0.1% in distilled H2O) 
Few seconds Millipore 
Few seconds 90 % Ethanol 
 
 Dehydration 
Few seconds 96 % Ethanol 
1 x 30 sec 96 % Ethanol 
1 x 3 min 100 % Ethanol 
1 x 5 min  100 % Ethanol 
3 x 5 min  Xylol 
 
 Embed with Eukitt 
Slides were embed with 2-3 drops of Eukitt, covered with a coverslip and dried O/N. Samples 
were analyzed with transmission light at the confocal microscope using a 40X magnification 
oil immersion objective and Leica LAS AF software. 
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3.6.3 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining 
To detect cell death within tissues, paraffin was removed and sections were re-hydrated as 
written in the rehydration step of Hematoxylin-eosin staining. Then, samples were heated by 
microwave in 0.1 M sodium citrate pH 6.0 at 350 W for 5 min. Samples were then washed 2 x 
2 min in PBS and incubated with 50 µl of TUNEL reaction mixture, prepared as described by 
the manufacturer of the In situ cell death detection kit, TMR red dUTP. Briefly, 4 parts 
Labelling solution were mixed with 1 part Enzyme solution and added to 5 parts Buffer 
solution. The staining was performed by incubating samples for 1h at 37°C in a humid 
chamber. For positive control, slides were pre-incubated with 3000 U/ml DNAse (in 50 mM 
Tris-HCl pH 7.5 and 1mg/ml BSA) for 10 min at RT. All slides were then washed 3 x 1 min 
in PBS, heated for 10 min at 70°C in PBS, washed again for 1 min in PBS and covered with 
12 µl Mowiol. A coverslip was applied and samples were stored at 4°C in the dark until 
detection at the confocal microscope. TMRM was excited at 543 nm and detected between 
570-630 nm. For bright field, transmission light was used. Images were detected with a 40X 
magnification oil immersion objective using Leica LAS AF software. 
3.7 Mitochondrial membrane potential and reactive oxygen species 
(ROS) production measurements 
MitoSOX Red reagent is a fluorogenic dye specifically targeted to mitochondria in living 
cells. Oxidation of MitoSOX Red by superoxide produces red fluorescence. 
Tetramethylrhodamine, methyl ester (TMRM) is a cell-permeant, cationic, red-orange 
fluorescent dye that is readily sequestered by active mitochondria. To detect ROS production 
and mitochondrial membrane potential changes upon incubation with inhibitors, 0.05 x 10
6
 
cells were seeded on 24 mm round coverslip in a 6 well plate O/N. The coverslip was then 
removed from the plate, placed in a sealed coverslip dish and incubated with 1 µM MitoSOX 
Red reagent or 20 nM TMRM in 1 ml DMEM w/o phenol red and w/o FCS for 20 min at 
37°C in the dark. Fluorescence was detected at the confocal microscope at t=0, then the 
different compounds were added and a 45 min long kinetic was acquired every 3 min. 
MitoSOX and TMRM were excited with a 543-nm laser and detected between 570-630 nm. 
For bright images, transmission light was used. Images were acquired through a 40X 
magnification oil immersion objective with a Leica SP5 confocal microscope and analyzed by 
the LAS AF software. 
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3.8 Transient transfection with siRNA 
To transiently transfect cells with siRNA, 0.02 x 10
6
 cells per well were seeded in a 24 well 
plate in complete medium O/N. Cells were then transfected using Lipofectamine 2000 
Reagent as indicated by the manufacturer. Briefly, 2 µl Lipofectamine reagent and 1 µg 
plasmid DNA (scramble-siRNA or siRNA for Kv1.3, Qiagen) per well were separately 
diluted in 75 µl Opti-MEM medium and incubated for 5 min at RT. Diluted Lipofectamine 
reagent was then gently added to the diluted DNA and incubated for 20 min at RT in the dark. 
In the meanwhile, medium of the cells was changed to DMEM without (w/o) phenol red and 
w/o FCS. Then, 150 µl DNA-lipid complexes were added drop by drop to the cells and 
incubated for 4h at 37°C. Medium was then replaced with complete DMEM and cells were 
incubated for 48h at 37°C. Cells were treated with different Kv1.3 inhibitors in DMEM w/o 
phenol red and w/o FCS for the desired time, then incubated with FITC-Annexin V (1:150) 
for 1h at 37°C and visualized at the fluorescence microscope with a 40X magnification oil 
immersion objective. Excitation beam was 488 nm for FITC and 543 nm for Alexa 555. FITC 
fluorescence was detected between 500-525 nm, whereas Alexa 555 was detected between 
590-630 nm. The Leica LAS AF software was used to acquire the images. 
3.9 Intracellular staining  
For intracellular staining of cells, 3 x 10
4
 cells/well were seeded on 12 mm round coverslip in 
a 24 well plate in 400 µl complete DMEM O/N. Cells were then washed 2 x PBS, fixed with 
2% PFA/PBS for 15 min at RT and washed 3 x PBS. After permeabilization with 0.1% 
Triton/PBS for 10 min, samples were washed 3 x PBS, blocked with 0.05% Tween/5% 
FCS/PBS for 10 min at RT and washed 1 x PBS. After incubation with primary antibodies in 
50 µl H/S+ 1% FCS for 45 min at RT, coverslips were washed 3 x PBS+ 0.05% Tween, 1 x 
PBS and incubated with corresponding secondary antibodies coupled to fluorescent dyes in 
H/S+ 1% FCS for 45 min in the dark at RT. After washing as described above for primary 
antibodies, samples were embedded with 8 µl Mowiol. Signals were detected at the confocal 
microscope with 100X magnification oil objective exciting with a 561 nm (Cy3) or 633 nm 
(Dylight649) laser. Detection was done between 570-620 nm for Cy3 and between 650-750 
nm for Dylight649.  Leica LAS AF software was used to acquire the images. 
3.10 Immunogold electron microscopy  
For immunogold staining, 0.5 x 10
6
 cells/ well were seeded in a 22 cm
2
 O/N. Cells were then 
washed 1 x PBS and fixed in 2% PFA+ 0.1% glutaraldehyde in 0.1 M cacoldylate buffer for 
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1h at RT. Samples were then washed 3 x 0.1 M cacodylate buffer, scraped and pelleted at 400 
x g for 5 min at RT. Samples were further processed by the Imaging Center of Essen 
(IMCES). Images were acquired by the IMCES with a Zeiss transmission electron microscope 
(EM 902A). 
3.11 In vivo techniques 
3.11.1 Mice 
All mice were 5-7 weeks old C57BL/6 wild-type mice. 
3.11.2 Glioma injection 
To perform glioma injection, GL261 cells were trypsinized from a sub-confluent flask and 
collected in medium at 400 x g for 5 min at 4°C. Cells were then washed 2 x H/S as above 
and re-suspended in H/S at a concentration of 2 x 10
7
 cells/ml. C57BL/6 mice were narcotized 
i.p. with 10 µl/g mouse FMM (Fentanyl, Midazolam and Medetomidin) and a clear cut was 
done with a scalpel on the head skin. A hole was drilled 2 mm lateral and 1 mm posterior to 
the bregma of the skull. After fixing the animal within a stereotaxic instrument, 1 µl (2 x 10
4
 
cells) cell suspension was injected in the striatum of the brain with a microliter syringe. 
Mouse skin was then sewed and a subcutaneous injection of 10 µl/g mouse antidote (Naloxon, 
Flumazenil and Atipamezol) was done. Mice were then monitored for glioma symptoms 
daily. 
3.11.3 Melanoma flank injection 
To inject melanoma in the flank of the mouse, B16F10 cells were detached with 1 ml Cell 
Dissociation buffer from a sub-confluent flask and collected at 400 x g for 5 min at 4°C. Cells 
were then washed 2 x PBS as above and re-suspended in PBS at a concentration of 1 x 10
6
 
cells/ml. Cells were divided in 50 µl aliquots (5 x 10
4
 cells/ mouse), carefully aspired in 1 ml 
insulin syringe and injected subcutaneously in the flank of the mouse. 
3.11.4 Mice treatments 
Treatments with Kv1.3 inhibitors were performed at days 5, 7, 9 and 11 post tumor injection, 
except where differently written. After dissolving in DMSO, drugs were administered 
intraperitoneally in 100 µl 0.9 % NaCl or orally, directly dissolved at 4 mg/ml in peanut oil, 
with a syringe connected to the appropriate needle. Mice were sacrificed at day 16 post tumor 
injection to measure tumor size, except where differently specified. In survival experiments, 
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mice were kept alive until manifestation of tumor growth symptoms (curved standing, almost 
no movement). Tumor volume was determined with a caliper as the product of length, width 
and height. Radiation (IR) was administered at a dose of 2 Gy only on the brain of the mouse. 
N-acetylcysteine (NAC) was injected i.p. at a concentration of 0.7 µg/g (Cst: 7 mg/ml). IR and 
NAC were administered 1h before treatment with Kv1.3 inhibitors. Cisplatin was given i.p. at 
a concentration of 0.5 µg/g (Cst: 1 mg/ml) together with the inhibitors. 
3.12 DNA techniques 
3.12.1 Mycoplasma PCR 
To test for mycoplasma contaminations, 1 x 10
6
 cells were re-suspended in 50 µl tissue lysis 
buffer and incubated for 3h at 56°C with smooth shaking. Then, lysate was boiled for 10 min 
at 96°C and supplemented with 100 µl RNA-se free H2O.  
The following mix was then prepared for the samples and for the positive control: 
H2O 18,75 µl 
10X PCR-Buffer B 2,5 µl 
25 mM MgCl2 1,5 µl 
10 mM dNTP’s 0,5 µl 
Primer 1 (5’ – GTG CCA GCA GCC GCG GTA ATA C- 3’) 0,25 µl 
Primer 4 (5’ –TAC CTT GTT ACG ACT TCA CCC CA- 3’) 0,25 µl 
Taq Polym. (SOLIS) 0,25 µl 
DNA 1 µl 
Tot. vol. = 25 µl 
Samples were then processed in the thermal cycler using the following program: 
1. 96°C 5 min 
2. 95°C 1 min 
3. 60°C 1 min 
4. 72°C 1,5 min 
5. 72°C 7 min 
6. 4°C pause 
 
3.12.2 Agarose gel electrophoresis 
To analyze PCR products, samples were supplemented with 4 µl 6X DNA loading buffer and 
loaded on a 0.8% agarose gel prepared in TAE buffer with 0.01 µg/ml ethidium bromide. 
Samples were run in parallel to 5 µl 1 kb marker at 80 V with constant V. DNA fragments 
were analyzed under UV light. 
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3.13 Statistics 
Data are shown as the mean ± SD. Since all values had a normal distribution, one-way 
ANOVA and Bonferroni’s multiple comparison test were applied. Significances are indicated 
by asterisks (* p≤0.05; ** p≤0.01; *** p≤0.001). 
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4 RESULTS 
4.1 Kv1.3 is expressed in the plasma membrane of different glioma cell 
lines 
The discovery of Kv1.3 in lymphocytes mitochondria and the finding that its inhibition was 
able to induce the intrinsic pathway of apoptosis even in absence of the proapoptotic proteins 
Bax and Bak, led Szabò’s group to investigate the role of mtKv1.3 in different types of 
cancer. Since then, different Kv1.3 inhibitors were successfully used to induce apoptosis in 
various cancers cell lines in vitro, ex vivo and in an in vivo model (Leanza L. et al 2012, 
Leanza L. et al 2013). 
To start the investigation, I initially checked whether different glioma cells, particularly the 
murine GL261 and the human A172 and LN308 glioma cell lines, expressed Kv1.3 channel in 
their plasma membrane. The three cell lines were surface-stained, as a first test, with a FITC- 
labeled anti-Kv1.3 antibody and signal of glioma cells was compared to that of Jurkat and 
K562 cells, used as positive and negative control, respectively. After 1h incubation with the 
antibody at 4°C, cells were analyzed by FACS. All three glioma cells showed a surface 
staining for Kv1.3. This signal was reduced compared to Jurkat cells, suggesting that these 
cells express a lower level of Kv1.3 (Figure 4.1a). The presence of Kv1.3 in glioma cells was 
then demonstrated also by analysis of enriched cell membrane fractions of the same cells by 
western blot. Particularly, cells were lysed with a NaCl-containing lysis buffer and after 
centrifugation the pellet of broken membranes was re-suspended and loaded on a 10% SDS-
PAGE with urea (Figure 4.1b).  
Figure 4.1. Kv1.3 is expressed in the plasma membrane of glioma cells. 
a) FACS staining of GL261, LN308 and A172 glioma cells. Cells were incubated with 1µg anti Kv1.3-FITC 
antibody for 1 h in ice at 4°C, in the dark. K562 and Jurkat cells were used as negative and positive controls, 
respectively. One representative histogram plot is shown (n=3). 
b) Western blot on enriched cell membrane fractions of GL261, LN308 and A172 cell lines. Samples were 
solubilized 1h at RT and loaded on a 10% SDS-PAGE with urea. After transfer, the PVDF membrane was 
incubated with a rabbit anti-Kv1.3 antibody (1:200 in TBS, Alomone) O/N at 4°C and developed with a HRP-
conjugated (1:20000 in TBS) rabbit secondary antibody. The Kv1.3 band was detected at 65 kDa. A rabbit anti-
Tom20 antibody (1:200 in TBS, O/N at 4°C) was used as loading control and developed with an anti-rabbit-HRP 
as above. Two independent studies with similar results were performed. Normalized Kv1.3 expression ± S.D. is 
shown in the histogram.  
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4.2 Kv1.3 is expressed in mitochondria of glioma cells 
Previous publications showed a correlation between Kv1.3 channel expression in the plasma 
membrane and its mitochondrial distribution in the inner mitochondrial membrane (Gulbins 
E. et al 2010, Leanza L. et al 2012, Leanza L. et al 2014a). To test whether Kv1.3 is also 
present in mitochondria of glioma cells, I isolated mitochondria of GL261 by differential 
centrifugation using a Percoll gradient. The obtained three different fractions (total extracts, 
membrane enriched fraction and Percoll purified mitochondria) were loaded on a gel and 
developed with an anti-Kv1.3 antibody. A band was detected at 65 kDa in the M1 fraction, 
corresponding to isolated mitochondria. Kv1.3 was also displayed in the fraction “4”, which 
corresponds to the enriched membranes (Figure 4.2a). Kv1.3 presence in mitochondria was 
further tested by confocal microscopy, after staining with an anti-Kv1.3 antibody. Some co-
localization of Kv1.3 with mitochondria, marked with an anti-Tim23 antibody, was found in 
GL261, A172 and LN308 glioma cells (Figure 4.2b). Further, location of Kv1.3 in 
mitochondria was shown in GL261 cells by immunogold electron microscopy (Figure 4.2c). 
 
 
 
 
 
 
 
Figure 4.2. Kv1.3 is expressed in mitochondria of glioma cells. 
a) 50 µg whole cell lysate (1), membrane enriched fraction (4) or Percoll purified mitochondria (M1) from 
GL261 cells were loaded on a 10% SDS-PAGE. The nitrocellulose membrane was incubated with an anti-Kv1.3 
(1:1000 in PBS, Pineda) antibody for 1h at RT and anti-rabbit-AP (1:25000 in PBS-T) antibody. The Kv1.3 band 
is detectable in the M1 fraction, corresponding to isolated mitochondria, at 65 kDa. Anti-Tim23 (1:500 in PBS 
for 1h at RT) and anti-tubulin alpha (1:1000 in PBS for 1h at RT) were used as loading control and both 
developed with an anti-mouse-AP (1:20000 in PBS-T). 2 independent studies with similar results were 
performed. 
b) After permeabilization with 0.1% Triton for 10 min, fixed glioma cells were stained with an anti-Kv1.3 
antibody (1:100, Affinity purified) and Cy3-anti rabbit secondary antibody (1:1000). Anti-Tim23 antibody 
(1:100), together with anti-mouse Dylight-649 antibody (1:500), was used to stain mitochondria.  
c) Immunogold labelling of GL261 cells showing location of Kv1.3 in mitochondria (M). After fixation, 
dehydration and infiltration, ultrathin sections were stained with an anti-Kv1.3 (1:20, Alomone) antibody and 
secondary gold-labeled anti-rabbit-IgG (1:20, Aurion). 
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4.3 Kv1.3 inhibitors PAP-1 and Psora-4 poorly induce cell death in 
glioma cells 
Recent works from Szabό and colleagues showed that membrane-permeant Kv1.3 inhibitors 
PAP-1, Psora-4 and clofazimine were able to successfully induce apoptosis in macrophages 
and different cancer cell lines, such as Jurkat (leukemic T lymphocytes), B16F10 (melanoma), 
SAOS-2 (sarcoma osteogenic), and ex vivo in B-CLL cells from chronic lymphocytic 
leukemia patients (Leanza L. et al 2012, Leanza L. et al 2013, Leanza L. et al 2014a). 
Moreover, clofazimine was shown to reduce melanoma growth of 90% in vivo (Leanza L. et 
al 2012). To get an initial evaluation of the sensitivity of glioma cells to the standard Kv1.3 
inhibitors, PAP-1 and Psora-4, I determined the effects of different concentrations of the 
drugs on cell death in GL261, LN308 and A172 by Trypan blue after 24h incubation. Since 
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many tumor cells extrude drugs by multidrug resistance pumps (MDR), MDR pump inhibitors 
(MDRi) Cyclosporine H (CSH) and probenecid were used in combination with Kv1.3 
inhibitors to prevent export of the drugs from the intracellular milieu and, thus, amplify the 
effect of Kv1.3 blockers. All three cell lines GL261 (Figure 4.3a), LN308 (Figure 4.3b) and 
A172 (Figure 4.3c) were rather resistant to the treatments, which induced at most 20% more 
cell death compared to the control. 
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Figure 4.3. Kv1.3 inhibitors PAP-1 and Psora-4 poorly induce cell death of glioma cell lines. 
GL261 (a), LN308 (b) and A172 (c) cells were treated with different concentrations of Kv1.3 inhibitors PAP-1 
and Psora-4 in combination with MDRi CSH and probenecid for 24h. Cell death was assessed by Trypan blue. 
The mean ± SD of 3 independent experiments is shown. Significant differences between treated and untreated 
samples are indicated by asterisks (* p≤0.05; ** p≤0.01, one-way ANOVA/Bonferroni). Percentage of cell death 
was calculated as follows: % cell death= (100 * number non-viable cells)/ total cells. 
4.4 The ‘new’ Kv1.3 inhibitors reduce survival of different glioma cell 
lines 
The efficacy and specificity of all newly synthesized Kv1.3 inhibitors were initially evaluated 
(refer to Patent number reported in Methods) by analyzing cell death of different cancer cell 
lines. Particularly, it was demonstrated by the authors of the patent that the new drugs were 
able to induce apoptosis in CTLL-2 Kv1.3, Jurkat, different PDAC (pancreatic ductal 
adenocarcinoma) cell lines and ex vivo B cells from chronic leukemia patients, but not in 
CTLL-2 pJK, K562 (myelogenous leukemia) cell lines and ex vivo healthy B cells, known to 
have low or no expression of Kv1.3. Moreover, apoptotic effects were obtained at lower 
concentrations than those used for PAP-1 and Psora-4 and without the use of MDR inhibitors. 
Before testing cell death by the ‘new’ Kv1.3 inhibitors on glioma cell lines, I evaluated their 
EC50 on GL261 after 24h of incubation by the use of MTT. The lowest EC50 concentration 
was measured for PAPTP (EC50= 1.32 µM) (Figure 4.4c), followed by clofazimine (EC50= 
2.52 µM) (Figure 4.4a) and PCARBMTP (EC50= 2.99 µM) (Figure 4.4d), finally by the 
highest EC50 for PEGME (EC50= 14.04 µM) (Figure 4.4b). 
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Figure 4.4. EC50 of clofazimine and ‘new’ Kv1.3 inhibitors. 
Gl261 cells were incubated with different concentrations of clofazimine (a) and the new Kv1.3 inhibitors 
PEGME (b), PAPTP (c) and PCARBMTP (d). After 24h, cell survival was determined by MTT assay. The mean 
± SD of 2 independent experiments is shown. The EC50 value was calculated by fitting the survival data of each 
drug with a second-order exponential decay function. The results are shown as percentage values normalized to 
the control. 
Further, I evaluated the sensibility of glioma cell lines to clofazimine and PAP-1 derivatives 
PEGME, PAPTP and PCARBMTP by measuring cell survival through MTT assay after 24h. 
Staurosporine, a classical inducer of the endogenous apoptotic pathway, was used as positive 
control. After treatment and incubation with MTT, absorbance was read at 490 nm. GL261 
(Figure 4.5a), LN308 (Figure 4.5b) and A172 (Figure 4.5c) resulted to be sensitive to the 
treatments, since all four inhibitors were able to induce a reduction of cell survival. A172 cell 
line resulted to be more resistant compared to the other two glioma cell lines. Clofazimine 
induced over 50% reduction of cell survival, even at the low dose of 1 M, in both GL261 
and LN308. The most effective inhibitor PAPTP, as shown above to have the lowest EC50, 
was able to reduce proliferation of A172 by almost 90%. PEGME seem to have a relevant 
effect only if used at higher concentrations in combination with clofazimine. These results, 
taken together, prove that the new Kv1.3 inhibitors PEGME, PAPTP and PCARBMTP induce 
cell death of glioma cell lines. 
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Figure 4.5. The ‘new’ Kv1.3 inhibitors reduce survival of glioma cell lines. 
Gl261 (a), LN308 (b) and A172 (c) glioma cell lines were treated with different concentrations of clofazimine 
and the new Kv1.3 inhibitors PEGME, PAPTP and PCARBMTP for 24h. Cell survival was determined by MTT 
assay. The mean ± SD of 3 independent experiments is shown. The results are shown as percentage values 
normalized to the control.  
4.5 The newly synthesized Kv1.3 inhibitors induce apoptosis and 
cytochrome c release of different glioma cell lines 
To test whether the reduced survival induced by clofazimine and PAP-1 derivatives were due 
to induction of apoptotic or necrotic cell death, GL261, A172 and LN308 cells were treated 
with clofazimine and PAP-1 inhibitors, and cell death was assayed by FACS using FITC-
coupled Annexin V (Figure 4.6a-c). PEGME, PAPTP and PCARBMTP were used alone or in 
combination with a low dose of clofazimine, which acts also as MDR inhibitor. After 24h 
incubation, cells were collected, stained 15 min at RT with FITC-Annexin V and analyzed by 
FACS. All three PAP-1 derivatives showed the ability to induce apoptotic death in all tested 
glioma cell lines. PAPTP and PCARBMTP were the most potent inhibitors, inducing 90% 
cell death in GL261 and LN308 cells after 24 hours, while clofazimine and PEGME displayed 
a weaker effect, inducing a maximum of 50% of apoptosis (Figure 4.6a-b). Compared to 
GL261 and LN308, and as previously seen in the cell survival assays, A172 resulted to be the 
most resistant cell line to treatment with clofazimine and PEGME, while PAPTP and 
PCARBMTP efficiently induced cell death also in this resistant cancer cell line (Figure 4.6c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. The ‘new’ Kv1.3 inhibitors induce apoptosis in different glioma cell lines.  
GL261 (a), LN308 (b) and A172 (c) glioma cells were treated with clofazimine and the ‘new’ Kv1.3 inhibitors 
PEGME, PAPTP and PCARBMTP. After 24h, cells were stained with Annexin V coupled to FITC, as reported 
in the Materials and Methods part, and the signal was detected in the FL1 channel. One representative 
experiment is shown in the upper panels, whereas the means ± S.D. of three independent studies are displayed in 
the lower graphs. Significant differences between treated and untreated samples are indicated by asterisks (*** 
p≤0.001, one-way ANOVA/Bonferroni). 
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Szabò and colleagues previously showed that Kv1.3 inhibitors PAP-1, Psora-4 and 
clofazimine are able to induce the mitochondrial pathway of apoptosis (Leanza L. et al 2012). 
To test whether the new Kv1.3 inhibitors were able to induce the intrinsic apoptotic pathway 
in glioma cells, I assessed cytochrome c release by Western blot after treatment with 
clofazimine and the most potent PAP-1 derivatives PAPTP and PCARBMTP. After 
incubation, cells were mechanically homogenized and nuclei and unbroken cells were 
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pelleted. Release of the mitochondrial cytochrome c was detected as 15 kDa band in the 
cytosolic fractions of treated GL261 after 16 h incubation with the inhibitors (Figure 4.7, left 
panel). The release was dose dependent, as shown by incubation of GL261 with different 
clofazimine concentrations (Figure 4.7, right panel). The classical intrinsic apoptosis inducer 
staurosporine was used as positive control. Taken together, these results show that PAP-1 
derivatives are able to induce the mitochondrial pathway of apoptosis in different glioma cell 
lines. 
 
 
 
Figure 4.7. Clofazimine and the ‘new’ Kv1.3 inhibitors induce cytochrome c release in glioma cells. 
Gl261 cells were treated for 16h with clofazimine and PAP-1 derivatives and processed as described in the 
Methods part. Mitochondrial and cytosolic fractions were loaded on a 12% SDS-PAGE, transferred to a PVDF 
membrane and developed with an anti-cytochrome c (1:2000 in TBS O/N at 4°C, 15 kDa) and anti-mouse-HPR 
secondary antibody. A mouse anti-GADPH (1:500 in TBS, O/N at 4°C, 38 kDa) and rabbit anti-Tom20 (1:1000 
in TBS O/N at 4°C, 20 kDa) were used as loading controls of, respectively, the mitochondrial and the cytosolic 
fractions, and developed with related HRP-conjugated secondary antibodies (anti mouse 1:10000 or anti rabbit 
1:20000 in TBS). The experiment was performed three times with similar results. 
 
4.6 PAP-1 derivatives induce apoptosis by specifically targeting Kv1.3  
To test whether the effects of Kv1.3 inhibitors on glioma cells were due to the specific 
targeting of Kv1.3, I transiently abolished Kv1.3 expression of glioma cells by using an 
siRNA against Kv1.3 coupled to Alexa 568 dye. The apoptotic effects upon treatment with 
the inhibitors were suppressed in Kv1.3-siRNA transfected cells, but not in the scramble-
siRNA transfected ones, confirming that the apoptotic effects seen after treatment with the 
compounds are due to their specific targeting of Kv1.3 in glioma cells (Figure 4.8). 
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Figure 4.8. Clofazimine and PAP-1 derivatives induce apoptosis by specifically targeting Kv1.3 in glioma 
cells.  
GL261 glioma cells were transiently transfected with either Alexa568-labeled siRNA control (scramble) (a) or 
Alexa 568-coupled siRNA against Kv1.3 (b). 48h after transfection, cells were treated for 24h with different 
Kv1.3 inhibitors or their derivatives and stained with FITC-Annexin V. Positive cells and siRNA transfected 
cells were detected by fluorescence microscopy as written in the Methods part. Transfection efficacy was 
demonstrated by fluorescence of the Alexa 568-siRNAs. The results are representative of three similar studies. 
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4.7 Membrane permeant inhibitors cause ROS increase and 
mitochondrial depolarization in glioma cells 
Since membrane permeant inhibitors are expected to target the mtKv1.3 and previous studies 
demonstrated the role of ROS in mitochondrial Kv1.3-mediated apoptosis (Szabo I. et al 
2008), I studied the effect of clofazimine on mitochondrial ROS production and mitochondrial 
membrane potential in GL261 glioma cells. After incubation with MitoSOX or TMRM dye, 
the inhibitor was added and cells were monitored for 45 min. A time dependent enhancement 
of MitoSOX fluorescence was detected in clofazimine treated GL261 but not in the control, 
indicating an increase in mitochondrial ROS production induced by the blocking of the 
channel (Figure 4.9a). Decrease in TMRM fluorescence after 30 min incubation with 
clofazimine indicated Kv1.3 inhibition dependent- mitochondrial depolarization (Figure 4.9b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Clofazimine induces mitochondrial ROS increase and mitochondrial depolarization in glioma 
cells. 
GL261 cells were incubated with either MitoSOX (a) or TMRM (b) for 20 min at 37°C in the dark. Then, 
clofazimine was added at t=0 and a 45 min long kinetics was acquired by detecting MitoSOX or TMRM 
fluorescence with confocal microscopy. The results are representative of two similar studies. 
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4.8 Clofazimine and PAP-1 derivatives do not reduce glioma growth 
in vivo 
To test whether clofazimine and PAP-1 derivatives are able to exert a cancer cell death effect 
also in vivo, I used an established syngeneic model, which does not require a deficient 
immune system and closely mimics growth characteristics of human GBM, including invasive 
and angiogenic properties (Jacobs V.L. et al 2011). Clofazimine (10 nmol/g) and PAP-1 
derivatives, PAPTP and PCARBMTP, were administered intraperitoneally (i.p.) at days 5, 7, 
9 and 11 post tumor injection and a survival curve was assessed (Figure 4.10a-b). Treatment 
with clofazimine was preceded by irradiation (2 Gy) to increase the permeability of the blood 
brain barrier for the drug. Furthermore, clofazimine was also administrated p.o. Neither i.p. 
and p.o. clofazimine nor the two PAP-1 derivatives were able to trigger a better survival rate 
compared to the untreated mice (Figure 4.10a-b). Considering the death induced in vitro by 
these compounds, an explanation for these negative results was suggested by the preliminary 
HPLC data (Figure 4.10c). Glioma injected mice treated with clofazimine were sacrificed 
after 2 h and compound amount in the brain, plasma and spleen was determined by HPLC. No 
clofazimine was detected in the brain of treated animals, suggesting that the drug does not 
reach the tumor tissues in vivo (Figure 4.10c). The same experiment was performed for 
PAPTP as well, but no detectable peaks were available, indicating no accumulation in the 
brain (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Clofazimine and PAP-1 derivatives do not reduce glioma growth in vivo. 
a) Glioma injected mice were left untreated (n=6) or treated with 10 nmol/g i.p. clofazimine alone or in 
combination with irradiation (IR, n=4). The mean of n independent experiments is reported in the graphs. 
b) Glioma injected mice were left untreated (n=3) or treated with 20 nmol/g p.o. clofazimine (n=3), 4 nmol/g i.p. 
PAPTP (n=3) or 8 nmol/g i.p. PCARBMTP (n=3) at days 5, 7, 9 and 11 post injection. The mean of n 
independent experiments is reported in the graphs. 
c) Glioma injected mice were treated with clofazimine i.p. or p.o. in DMSO or peanut oil at day 16 after tumor 
injection. 2h after administration, mice were sacrificed and brain, blood and spleen were removed. After 
processing as described in the Methods part, samples were analyzed by HPLC. The means ± SD (n=2) are 
reported in the graphs. HPLC analysis was performed in Padua (Italy). 
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4.9 In vivo accumulation of clofazimine and PAP-1 derivatives in 
different organs 
According to previous results, I decided to test whether PAP-1 derivatives are able to reach 
the different mouse organs, also to get a larger overview of Kv1.3 inhibitors accumulation in 
vivo. For these reasons, I treated mice with PEGME plus low dose of clofazimine (as MDRi), 
PAPTP, PCARBMTP or the precursor, PAP-1. After 2h, 4h or 8h post injection, mice were 
sacrificed and blood, brain, heart, liver, spleen and kidney were removed, processed as written 
in the Methods part and analyzed by HPLC (Figure 4.11a-d). PEGME was not detected in 
treated mice while only clofazimine was revealed (Figure 4.11c). PCARBMTP, the pro-drug 
compound, is not stable in blood and organs and is rapidly hydrolyzed to PAP-1-OH, which 
has been detected by the HPLC already 2 h after mice injection (PAPOH, Figure 4.11b). 
Contrarily, PAPTP, which is a stable drug, was detected in the samples of PAPTP treated 
mice where present, but was quite fast eliminated by the body as shown in Figure 4.11a. None 
of the compounds was present in the brain (Figure 4.11a-d). Almost no accumulation of the 
four inhibitors was also seen in heart and blood. All four inhibitors were mostly present in 
liver and kidney. From 2h to 8h, all derivatives concentration in tissues decreased, except for 
clofazimine. In blood, PAPTP disappeared after 2h, PAP-1-OH after 4h, but not clofazimine 
and PAP-1, which were present until 8h. 
 
 
 
 
 
 
 
 
 
Figure 4.11. Clofazimine and PAP-1 derivatives in vivo accumulation in different organs. 
Mice were treated once with i.p. 5 nmol/g PAPTP, 10 nmol/g PCARBMTP, 10 nmol/g PEGME+ 2 nmol/g 
clofazimine or 20 nmol/g PAP-1 and sacrificed 2h, 4h or 8h post injection. Blood, brain, heart, liver, spleen and 
kidney were collected and processed for HPLC analysis as described in Methods. Accumulation of PAPTP (a), 
PCARBMTP (PAPOH) (b), clofazimine (c) and PAP-1 (d) are reported in the histograms as the mean ±SD of 
three independent experiments. HPLC analysis was performed in Padua (Italy). 
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4.10 PAP-1 derivatives prevent melanoma growth in vivo  
The groups of Prof.s Szabό and Gulbins showed that the Kv1.3 inhibitor clofazimine was able 
to induce 90% reduction of tumor size in a syngeneic melanoma mouse model (Leanza L. et 
al 2012). Given their lower toxicity and higher specificity, I wanted to test the effects of PAP-
1 derivatives in the same tumor model. Initially, in vitro experiments with B16F10 cells were 
performed by Szabó and colleagues treating the cells with PEGME, PAPTP and 
PCARBMTP, as shown in Figure 4.12. The treatments revealed a higher efficiency of the new 
synthesized compounds in inducing apoptotic cell death at concentrations 20 times lower 
compared to the precursor PAP-1 and without the addition of any MDR inhibitor. Indeed, 
PAPTP and PCARBMTP were able to trigger 60 % cell death in B16F10 cells already at 1 
µM, while PAP-1 was effective at 20 µM in combination with MDR inhibitors. Furthermore, 
the specificity of these compounds for Kv1.3 was confirmed in B16F10 cells in which Kv1.3 
expression was downregulated by siRNA transfection (Figure 4.13). In cells in which Kv1.3 
expression was abolished, neither PAP-1 nor its derivatives were able to induce cell death. 
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Figure 4.12. PAP-1 derivatives efficiently kill B16F10 cells. 
B16F10 cells were incubated for 24h with different concentrations of PAP-1 and its derivatives (PAPTP, 
PCARBMTP, PEGME) alone or in combination with MDR inhibitors (MDRi: CSH 4 uM). Cell death was 
assayed by staining with a FITC-labeled Annexin V using a fluorescent microscope Leica DMI 4000. Values are 
means ± S.D. of 4 different experiments (performed in Padua by Luigi Leanza). 
 
 
 
Figure 4.13. Downregulation of Kv1.3 prevents cell death effects induced by PAP-1 and its derivatives.  
B16F10 cells were transfected with siRNA scramble or against Kv1.3. 48h after transfection, cells were 
incubated for 24h with the PAP-1 and its derivatives as indicated. Cell death was assayed by staining with a 
FITC labeled Annexin V using a fluorescent microscope Leica DMI 4000. Values are means ± S.D. of 4 
different experiments (performed in Padua by Luigi Leanza). 
According to the in vitro data, I moved to the in vivo model to test the ability of PAP-1 
derivatives to reduce melanoma growth in vivo. These experiments were performed in 
collaboration with Dr. Luigi Leanza from the University of Padua (Italy). Indeed, C57BL/6 
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mice were subcutaneously injected with 5 x 10
4
 B16F10 melanoma cells and treated i.p. with 
PAP-1 and its derivatives, PAPTP, PCARBMTP or PEGME (the latter, together with a lower 
dose of clofazimine, which can also act as MDR inhibitor) at days 5, 7, 9 and 11 post tumor 
cells injection. After 16 day, tumor volume was determined. All three derivatives strongly 
reduced tumor growth compared to the untreated control, whereas PAP-1 alone had no effect. 
Both PAPTP and PCARBMTP reached 90% tumor reduction, while PEGME 60% (Figure 
4.14a). Importantly, no side effects were induced by the compounds in brain, heart, liver, 
inguinal lymph nodes (ILN), kidney and spleen of treated animals, as shown by histological 
staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
(Figure 4.14b-c). 
 
 
Figure 4.14. PAP-1 derivatives reduce B16F10 melanoma tumor in vivo.  
a) Mice were injected with 5x10
4
 B16F10 cells and treated i.p. with 5 nmol/g PAPTP (n=13), 10 nmol/g 
PCARBMTP (n=7), 10 nmol/g PEGME + 2 nmol/g clofazimine (n=11)  and 20 nmol/g PAP-1 (n=3) at days 5, 7, 
9 and 11 post cells injection. After 16 days, tumors were removed and measured. In the histogram, the means ± 
S.D. of  independent studies are reported. In the lower panel, representative tumors from PAP-1 derivatives 
treated mice are shown. Significant differences between treated and untreated samples are indicated by asterisks 
(*** p≤0.001, one-way ANOVA/Bonferroni). 
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Figure 4.14. PAP-1 derivatives reduce B16F10 melanoma tumor in vivo.  
b) Haematoxylin-eosin staining of brain, heart, liver, ILN, kidney and spleen of untreated and PAP-1 derivatives 
treated mice.  
c) TUNEL staining of brain, heart, liver, spleen and kidney of untreated and PAP-1 derivatives treated mice. 
DNAse was used as positive control. 
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4.11 Kv1.3 inhibitors synergize with chemotherapeutic treatment to 
reduce melanoma in vivo 
The use of Kv1.3 inhibitors is thought to be in concomitance with a chemotherapeutic drug, to 
improve the specificity and thus amplifying the effects of the treatment. Thus, we tested 
whether treatment with PAP-1 derivatives was able to improve the effects of the normally 
used chemotherapeutic drug in melanoma treatment, cisplatin. We decided to reach the 
possible tumor remission by combining cisplatin plus PAPTP, since this derivative showed 
the most powerful effects in vitro and in vivo. Mice were injected with B16F10 melanoma 
cells and treated, as described above, with cisplatin alone or together with PAPTP. The 
combination of cisplatin and the derivative induced a reduction of tumor growth higher than 
the one achieved with cisplatin alone, reaching around 95% of tumor volume reduction 
(Figure 4.15). 
 
 
Figure 4.15. PAP-1 derivatives synergize with chemoterapeutic drug cisplatin in the reduction of 
melanoma growth.  
Mice were injected with 5x10
4
 B16F10 cells and left untreated (n=4), treated i.p. with 0.5 µg/g cisplatin (n=4) or 
with 0.5 µg/g cisplatin + 5 nmol/g PAPTP (n=5) at days 5, 7, 9 and 11. Tumors sizes were determined after 16 
days post B16F10 cells injection. The means ± S.D. of independent studies are reported. Significant differences 
between treated and untreated samples are indicated by asterisks (*** p≤0.001, one-way ANOVA/Bonferroni). 
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4.12 Antioxidants prevent melanoma reduction induced by PAP-1 
derivatives in vivo 
Previous observations showed that a synergistic effect between Kv1.3 inhibition and the redox 
state of the cells is necessary for the induction of cell death (Leanza L. et al 2013). Since 
cancer cells have a higher redox level than healthy ones, mtKv1.3 inhibition results in a 
sufficient ROS increase to reach the critical threshold necessary for the activation of apoptotic 
cell death. On the contrary, non-tumorigenic cells, which show normal ROS levels, even after 
mtKv1.3 inhibition and consequent increase of ROS, cannot reach the necessary threshold 
required to induce cell death. This mechanism could explain the specificity observed with 
Kv1.3 inhibitors for cancer cells. Importantly, ROS scavenging in cancer cells prevented the 
death effects induced by Kv1.3 inhibitors. Here, I tested in vivo whether pre-treatment with 
the anti-oxidant N-acetylcysteine (NAC) was able to protect tumor cells from PAP-1 
derivatives effects. In parallel experiments similar to the ones described above, we pre-treated 
mice for 1 h with NAC before injecting PAP-1 derivatives. After 16 days, tumor size 
determinations revealed no significant differences between treated and untreated, 
demonstrating that a reduction of ROS concentration prevented tumor cell death by PAP-1 
derivatives in vivo. These results confirmed the presence of a synergistic effect between ROS 
level in the tumor and Kv1.3 inhibition in vivo (Figure 4.16). 
 
Figure 4.16. Anti-oxidant N-acetylcysteine prevented the cell death effects of PAP-1 derivatives on 
melanoma tumor growth in vivo.  
B16F10 cells were injected in mice, those were treated at days 5, 7, 9 and 11 post cells injection with the 
antioxidant N-acetylcysteine (0.7 µg/g) alone or in combination with different PAP-1 derivatives (10 nmol/g 
PCARBMTP, 5 nmol/g PAPTP and 20 nmol/g PAP-1). After 16 days, the tumors were removed and the sizes 
were determined. The means ± S.D. of three independent studies are reported. 
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4.13 PAP-1 derivatives do not change the composition of immune cell 
sub-population within the tumor 
PAP-1 derivatives were able to selectively eliminate cancer cells in vivo, without inducing 
any side effect in different healthy organs. Nevertheless, I checked their possible effects on 
the immune system cells, e.g. B and T lymphocytes and macrophages, which have also been 
demonstrated to express functional Kv1.3. I verified the possible changes in the composition 
of immune cells populations within the tumor of mice treated with PAP-1 and its derivatives, 
separating by FACS using the staining from different and specific antibodies, the following 
sub-populations of immune cells: T helper cells, cytotoxic T cells, B lymphocytes, regulatory 
T cells (Treg), macrophages (M1/M2) and neutrophils. The analysis revealed no significant 
differences in the number and in the distribution of the different sub-populations of immune 
cells in treated mice compared to the controls (Figure 4.17). These data demonstrated that 
PAP-1 derivatives specifically act targeting mtKv1.3 within the tumor cells, without affecting 
the cells responsible for the immune surveillance. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. PAP-1 derivatives treatment does not alter the immune cell sub-populations within the tumor. 
B16F10 cells were injected in mice, which were treated once after 10 days post cells injection with PAPTP (5 
nmol/g), PCARBMTP (10 nmol/g) or PAP-1 (20 nmol/g). After 24h, the tumor was removed, homogenized and 
filtered. 1x10
6
 cells were collected and stained for the following sub-populations of immune cells: T helper 
(CD3, CD4) or cytotoxic T cells (CD3, CD8) (a), B cells (CD19, MHCII) (b), Treg (CD4, CD25, FoxP3) (c), 
M1/M2 macrophages (CD11b, F4/80, CD204) (d), neutrophils (CD11b, CD11c, Ly6G) (e). The numbers of the 
different cell subpopulations were obtained by FACS analysis. The means ± S.D. of four independent studies are 
reported. Results are shown as the fold change of the different populations in relation to the mean value of the 
untreated. 
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5 DISCUSSION 
In the present study I showed that different derivatives of the membrane permeant Kv1.3 
blocker PAP-1 are able to induce apoptosis in glioma cell lines and prevent melanoma growth 
in vivo. After checking Kv1.3 presence in their mitochondria, I used the standard Kv1.3 
inhibitors PAP-1, Psora-4 and clofazimine, or the newly synthesized PAP-1-derivatives 
PEGME, PCARBMTP and PAPTP, to assess glioma cell lines for apoptotic cell death, 
including the characteristics of the intrinsic pathway. To evaluate their efficacy on tumor 
growth in vivo, I applied the new inhibitors to two kinds of syngeneic models, melanoma and 
glioma. In concomitance, to gain insight into the drugs accumulation mechanism, I did a 
pharmacokinetic analysis which helped me to explain the in vivo results. 
5.1 Kv1.3 expression in glioma 
The present study showed that glioma cell lines, in particular GL261 (murine), A172 and 
LN308 (human), express Kv1.3 in their plasma membrane (PM) and mitochondria. To better 
underline the presence of the channel in the PM, which displays -as all other channels- very 
low concentrations compared to soluble proteins, I used a protocol which allows the 
enrichment of the overall cell membrane fractions by eliminating the soluble portion of 
proteins. Percoll-purified mitochondria analyzed by western blot demonstrated a significant 
increase of Kv1.3 expression compared to total extracts and enriched membrane fraction from 
the same samples. Some co-localization of Kv1.3 with mitochondria was shown by confocal 
microscopy by using a mitochondrial marker (Tim23). To remove the background that arises 
from overlapping emission wavelength, acquisition in the sequential scanning mode was 
performed, which permits the separate detection of different channels fluorescence, which is 
later added up. Biochemical observation was further confirmed by immunogold electron 
microscopy, showing Kv1.3 in mitochondria of GL261 cells.  
Few groups investigated Kv1.3 in glioma until now. My results are in accordance with 
previous findings which showed Kv1.3 expression in a variety of glial tumors, beside 
proliferative normal glial cells (Preussat K. et al 2003). Particularly, starting from the 
knowledge that voltage-gated K
+
 channels (Kv) subtypes Kv1.3 and Kv1.5 contribute to 
growth-related properties of normal glia (Attali B. et al 1997, Chittajallu R. et al 2002), 
Preußat and colleagues conducted a screening of Kv1.3 and Kv1.5 channels expression in 
different human glioma samples, demonstrating an inverse correlation with glioma 
malignancy grades for Kv1.5 (e.g. high channel expression in low grade tumor), though no 
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correlation was found for Kv1.3 (Preussat K. et al 2003). These findings were also confirmed 
by the group of Felipe, which showed an increased Kv1.5 expression in different human 
cancers compared to the normal counterpart, whereas Kv1.3 level did not change, or was 
either decreased (Bielanska J. et al 2009). In other tissues and tumor types, however, a 
correlation was found. An upregulation of Kv1.3 gene expression was found in activated B-
like diffuse large B cell lymphoma by Alizadeh and colleagues (Alizadeh A.A. et al 2000). A 
positive correlation between Kv1.3 expression level and breast cancer stage was also found 
(Abdul M. et al 2003, Jang S.H. et al 2009). However, Brevet and colleagues found an inverse 
correlation, where normal breast tissues expressed more Kv1.3 than the cancerous one (Brevet 
M. et al 2008). Down-regulation of Kv1.3 in high grade tumor was also found in prostate 
cancers and pancreatic adenocarcinomas (Abdul M. et al 2006, Brevet M. et al 2009).  
This is the first study to put evidence on the mitochondrial presence of Kv1.3 in glioma cells, 
which was not evaluated in the reverse-transcriptase studies of the previous group (Preussat 
K. et al 2003). In accordance to my findings, other groups already suggested dual localization 
of the protein, both in PM and mitochondria, in hippocampal cells, macrophages, breast 
cancer MCF-7 and prostate cancer PC3 cell lines (Bednarczyk P. et al 2010, Gulbins E. et al 
2010, Vicente R. et al 2006). However, the mechanism of dual targeting, and whether this is 
used by other Kv channel types, is still not known. Until now, only Kv1.5 was reported to 
display organellar localization but the exact site was not addressed (Bonnet S. et al 2007). 
Potassium channels other than Kv1.3, including BKCa, IKCa and TASK-3, have also been 
found to display a dual localization (De Marchi U. et al 2009, Kovacs I. et al 2005, Rusznak 
Z. et al 2008, Xu W. et al 2002). 
5.2 Induction of apoptosis through mtKv1.3 inhibition in different 
glioma cell lines 
I demonstrated that mitochondrial Kv1.3 (mtKv1.3) expressing glioma cells GL261, LN308 
and A172 are not significantly susceptible to Kv1.3 standard inhibitors PAP-1 and Psora-4, 
whereas undergo massive apoptosis when treated with the PAP-1 derivatives PEGME, 
PCARBMTP and PAPTP. Compared to PAP-1 and Psora-4, which displayed minimal or no 
induction of cell death up to 20 µM, PEGME, PCARBMTP and PAPTP showed higher 
selectivity even at low concentrations (1 and 5 µM). Moreover, unlike PAP-1 and Psora-4 
blockers, PAP-1 derivatives could exert their effect in absence of multidrug resistance pump 
inhibitors (MDRi). Additional preliminary studies proved the new blockers selectivity up to 
10 µM. Furthermore, they showed on different cancer cell lines that their effect was the same, 
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if not enhanced, when the derivatives were used without MDRi (see Patent in Materials and 
Methods). The higher effectiveness of the new compounds, with respect to the standard 
psoralens PAP-1 and Psora-4, has to be ascribed to their chemical properties, which improve 
the problems of low water solubility and consequently need of high dosages, and target them 
to the direct site, the mitochondria, by a positive charge attached. Indeed, the engineered 
groups of the new inhibitors confer them, respectively, a better water solubility and a lower 
partition coefficient (by the polyethylene glycol, PEG group, to PEGME), and the capability 
to be targeted to mitochondria (by the tetraphenylphosphonium, TPP group, to PCARBMTP 
and PAPTP), thus allowing a more efficient crossing of biological membranes and targeting 
of the mitochondrial channel. Furthermore, the increased ability of PAPTP and PCARBMTP 
to reach mitochondria also represents an advantage, since it avoids side effects that could arise 
from drug accumulation in the plasma membrane or in other subcellular compartments where 
the channel is present. Moreover, PCARBMTP has been developed as pro-drug: indeed, it has 
a big TPP ion bound to PAP-1 by a carbamate linker, which can be hydrolyzed inside the cells 
by esterase, thus releasing the free PAP-1 directly in the right site of action. Importantly, this 
large modification leads to a lower affinity in Kv1.3 inhibition, hence decreasing its capability 
to block the plasma membrane Kv1.3, thereby reducing its possible effects on immune system 
cells. Nevertheless, PCARBMTP is more labile and less efficient compared to the more stable 
PAPTP. Clofazimine needs to be discussed separately. Indeed, since clofazimine is also 
working as MDR inhibitor (MDRi), it can reduce cell survival at lower concentrations than 
the standard inhibitors PAP-1 and Psora-4. This drug can induce apoptosis also in other 
manners than specific targeting the mtKv1.3, e.g. via direct caspase-3 activation or in a 
phospholipase-dependent manner (Fukutomi Y. et al 2011, Van Rensburg C.E. et al 1994). 
However, the apoptotic effect I saw after glioma cells treatment specifically depends on 
Kv1.3 inhibition, since the siRNA downregulation of Kv1.3 prevents cell death upon 
treatment with the compounds. Specificity for Kv1.3 was shown in the same experiment also 
for all other newly synthesized inhibitors.  
Regulation of apoptosis by voltage gated potassium (Kv) channels has already been shown in 
rat retinal ganglion, where Kv1.1 or Kv1.3 siRNA transfection showed to greatly reduce 
apoptosis after optic nerve transection (Koeberle P.D. et al 2010). A role for apoptosis 
induction through mitochondrial channels was ascribed to Kv1.1, Kv1.5, Kv2.1 and Kv11.1 
(hERG). For example, increased expression of Kv1.1 was found in apoptotic cerebellar 
granular neurons, whereas Kv1.1 knock-down in these cells increased neuron viability (Hu 
C.L. et al 2008). In contrast to these results, overexpression of Kv1.5 in human pulmonary 
artery smooth muscle cells enhanced apoptosis, whereas its pharmacological inhibition 
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prevented it. Moreover, Szabò’s group demonstrated that inhibition of Kv1.5 and Kv1.3 by 
membrane-permeant drugs induced apoptosis in macrophages expressing these channels in 
their mitochondria (Leanza L. et al 2012). Although the mechanism is still not yet clarified, 
inhibition of hERG by an antihypertensive drug has been shown to induce apoptosis in hERG 
expressing human embryonic kidney (HEK) cells (Thomas D. et al 2008). Furthermore, 
hERG targeting with a specific blocker impaired the chemokine receptor essential for 
leukemic cell survival and enhanced mouse survival in vivo (Pillozzi S. et al 2011).  
Selective induction of IMM permeabilization by other channels than Kv has also been 
considered in many studies. Opening of the mitochondrial permeability transition pore 
(MPTP) has been induced in cultured cells by a large number of compounds. However, when 
transferring the results in vivo, noxious side-effects, for example on nervous system, have to 
be considered. Data regarding in vivo anti-tumor activities by natural MPTP openers 
compounds are available (Fulda S. et al 2010) and some MPTP-targeting molecules are 
currently being tested in clinical trials for the treatment of refractory tumors (Brenner C. et al 
2012, Elliott M.A. et al 2012). The large conductance Ca
2+
-activated K
+
 channel BKCa (KCa 
1.1), present in mitochondria, ER and Golgi, might also favour MPTP opening, since Bax 
showed to inhibit it (Cheng Y. et al 2011). Moreover, a BKCa channel opener has been shown 
to induce glioma cell death, accompanied by increased respiration and mitochondrial 
depolarization (Debska-Vielhaber G. et al 2009). The IKCa inhibitor TRAM-34 showed to 
increase sensitivity to death receptor ligand TRAIL in melanoma, which could be exploited in 
its treatment in co-administration, given that both drugs are safe (Quast S.A. et al 2012). 
Overexpression of the mitochondrial Ca
2+
 uniporter (MCU), responsible for the low affinity 
uptake of Ca
2+
 into the mitochondrial matrix, has been shown to increase apoptosis upon 
H2O2 or C2-ceramide treatment (De Stefani D. et al 2011), whereas its downregulation 
showed increased resistance to apoptosis in colon cancer cells (Marchi S. et al 2013). Finally, 
compromised mitochondrial function and cell survival were seen in melanoma cells that 
transiently downregulated TASK-3 (tandem pore domain K
+
-channel) by transfection. 
However, it has still to be clarified whether this channel will be a useful oncological target, 
since no highly specific modulators are available (Kosztka L. et al 2011). Intracellular ion 
channels other than mitochondrial ones have also been ascribed as regulators of apoptosis. For 
example, overexpression of the intracellular chloride channel CLIC4/mtCLIC can be found, 
beside IMM, in the cytoplasm, ER and nucleus. There, it has been shown to induce apoptosis 
through loss of membrane potential, whereas its reduced expression and nuclear localization 
in cancer cells is associated with altered redox state (Suh K.S. et al 2012).  
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In the OMM, the pore mitochondrial apoptosis-induced channel (MAC), whose diameter and 
activity onset was shown to correlate with cytochrome c release and Bax translocation in 
apoptotic cells, is considered as a target for cancer therapies, even if specific MAC activators 
are not available yet (Martinez-Caballero S. et al 2009, Peixoto P.M. et al 2012). Formation of 
a large pore consisting of voltage dependent anion channel (VDAC) in the OMM and 
Bax/Bak was also proposed to participate to cytochrome c release, even if also dimers or 
oligomers of VDAC1 isoform could exert this function (Shoshan-Barmatz V. et al 2010, 
Tsujimoto Y. et al 2000). Since tumor cells have been seen to exhibit an increased VDACs 
expression, together with augmented glycolysis, the hexokinase (HK)-2–VDAC complex has 
also been considered as major oncological target, and different mitochondria-HK2 
dissociating drugs have been used. Particularly, the plant hormone methyl jasmonate (MJ) has 
been shown to exert anticancer activity in preclinical studies (Fulda S. et al 2010). However, a 
search for compounds directly targeting VDAC still has to be performed. 
In this study, I showed that clofazimine and PAP-1 derivatives-induced apoptosis of glioma 
cells is followed by mitochondrial depolarization, mitochondrial ROS increase and 
cytochrome c release. Indeed, as already shown by the group of Szabò (Szabo I. et al 2008), 
the blocking of potassium influx via mtKv1.3 hyperpolarizes the mitochondrial membrane, 
since protons efflux driving the respiratory chain is not anymore compensated by the 
electrophoretic flux of positive charges. This increases mitochondrial ROS production, which 
can further lead to MPTP opening and depolarization of the mitochondrial membrane. Also, 
ROS can favor cytochrome c release. In my case, it is clear that PAP-1 derivatives contribute 
to cell death through a mtKv1.3-dependent specific ROS increasing effect, since it was 
previously demonstrated that ROS do not increase when Kv1.3 inhibitors are added to Kv1.3-
deficient cells (Leanza L. et al 2012). 
5.3 PAP-1 derivatives are not able to prevent glioma growth in vivo 
The present study shows that clofazimine and PAP-1 derivatives, whereas inducing cell death 
in different glioma cell lines, are not able to prevent glioma growth in vivo. The inability of 
these compounds to confer a better survival rate can be ascribed to their lack of ability to 
reach the brain. Indeed, the HPLC data clearly revealed no accumulation of clofazimine or 
PAP-1, as well as its derivatives, in the brain of treated mice. To investigate whether a tumor-
induced altered blood brain barrier (BBB) could facilitate drug delivery to the brain, I 
measured clofazimine and PAPTP accumulation in mice injected with glioma, but no 
improvement in mice survival was seen (Wolburg H. et al 2012). Moreover, combination of 
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clofazimine treatment with irradiation, which has previously been shown to enhance BBB 
disruption, was not able to ameliorate the survival rate (Li Y.Q. et al 2003). Siegal and 
colleagues found increased vascular permeability in mice spinal cord 18h after a single dose 
of 15 Gy (Siegal T. et al 1996). The group of Wong demonstrated acute BBB disruption in the 
CNS 24h after a 50 Gy dose, and that disruption of the BBB was associated in a dose-
dependent manner to that of spinal cord of mice (Li Y.Q. et al 2003). Although they represent 
very high doses, we chose 2 Gy to avoid influence of radiation on tumor growth outcome 
(Ganai S. et al 2009). Moreover, 2 Gy is the dose currently used in humans for non-
myeloablative bone marrow transplantation to suppress the host immune system (Thomas 
E.D. et al 1982). Thus, the inefficacy of the drugs administered in presence of the tumor, as 
well as the combined treatment, could be ascribed to the chemical properties of the 
compounds, which prevent them from retention within the brain tissues. Regarding 
clofazimine, Mansfield already reported the crossing of the BBB by the compound in very 
small amounts (Mansfield R.E. 1974), whereas a more recent multiscale bio-distribution 
analysis revealed no accumulation of the drug in brain (Baik J. et al 2013). Since the brain is, 
compared to other organs such as blood, a highly lipophilic organ, due to the high presence of 
cells and membranes, it is expected that clofazimine, which is highly lipophilic, is strongly 
retained. Thus, it is likely that the timing and dose chosen for radiation did not properly 
disrupt the BBB. 
Until now, few groups used specific K
+
 channel inhibition to reduce tumor growth in vivo in 
glioma. Mostly, K
+
 channels were used to induce cell death by targeting the plasma 
membrane channel. In a recent study, Michelakis and colleagues successfully applied the 
small molecule dichloroacetate (DCA), which indirectly upregulates Kv1.5 in a NFAT 
(nuclear factor of activated T cells) mechanism in the plasma membrane leading to apoptosis, 
in humans (Michelakis E.D. et al 2010). Beside this study, the use of a Kv channel inhibitor 
was never tested in vivo in glioma. This represents the first attempt to test the ability of a Kv 
channel inhibitor to exert an apoptotic effect on glioma growth in vivo.  
5.4 PAP-1 derivatives accumulation in organs 
Previous in vitro stability experiments on PAP-1 derivatives demonstrated that PAP-1 and the 
EsaGME (PEGME) and PAPTP derivatives are stable at least 24h at 37°C both in PBS and in 
rat blood, whereas the TPP-carbamoyl PCARBMTP hydrolyzes slowly in PBS (50% 
hydrolized in 24h) but rapidly in rat blood (50% in 30 min). The analysis of the accumulation 
after in vivo treatment with the different compounds firstly revealed that none of the tissues 
DISCUSSION 
80 
was able to retain PEGME. The absence of PEGME in the recovery values could be due with 
more probability to its rapid elimination from the organism than to a shorter life-time in vivo. 
As expected from the in vitro studies, there is no trace of PCARBMTP but only of its 
hydrolysis product, PAP-1-OH. This compound is largely present in kidney and liver, 
probably because of the phenol group functionality, which renders it an optimal metabolizing 
site, and because compounds have been injected intraperitoneally. Clofazimine accumulates 
in heart, liver, spleen and kidney but differently from all other compounds, its concentration 
doesn’t decrease from 2 to 8 hours. Accumulation of clofazimine was previously shown in 
humans in liver, spleen and kidney and later confirmed also in mice liver and spleen (Baik J. 
et al 2013, Mansfield R.E. 1974). This drug has an elevated partition coefficient (logP˃7), 
which correlates with a high lipophilicity, reduced solubility and very long pharmacokinetic 
half-life, even due to its capability to accumulate in biological membranes. The consequent 
lipophilic partitioning into adipose tissue leads to increased bioaccumulation and worsen 
pharmacokinetic properties. Thus, even if it is a weak basic molecule, likely concentrating in 
acidic organelles, a large fraction of the drug can also distribute in organelle membranes (Baik 
J. et al 2013). It has already been shown that clofazimine accumulates in drug induced 
autophagosome-like drug-membranes aggregates (Baik J. et al 2011). The rapid elimination of 
PAP-1 derivatives from the organs, included liver and spleen, can be considered as an 
advantage, since then they cannot exert a toxic effect. Especially, the lack of accumulation of 
the compounds in the heart should avoid cardiotoxicity (as observed in preliminary 
electrocardiogram experiments by Szabò’s group), which represents the main side effect when 
using Kv1.3 blockers or, more in general, inhibitors for potassium channels, such as Kv11.1 
(hERG), which are highly expressed in the cardiac tissue. Particularly, cardiotoxicity for the 
heart is usually due to PAP-1 interaction with Kv1.5 (PAP-1 has 23-fold selectivity for Kv1.3 
over Kv1.5), while clofazimine inhibits Kv1.5 only at high concentrations, with an EC50˃ 
10µM (Schmitz A. et al 2005).  
5.5 PAP-1 derivatives prevent melanoma growth in vivo 
In this study, I demonstrated that PAP-1 derivatives PEGME, PAPTP and PCARBMTP are 
able to induce from 60% up to 90% tumor reduction in an orthotopic melanoma model. None 
of the PAP-1 derivatives induced abnormalities in different organs, confirming the safety of 
these drugs. PAP-1 already showed no histopathological alterations in Kv1.3-expressing 
tissues and no hematological or serum chemistry changes in long term toxicity studies, 
demonstrating that Kv1.3 has a very selective pharmacology and appears to be a relatively 
safe therapeutic target (Azam P. et al 2007, Beeton C. et al 2006). This can be due to channel 
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redundancy and different affinity in the targeting of Kv1.3-heteromultimers by the inhibitors 
(Szabo I. et al 2010). Beside the studies on the different tumor models done by our group, 
clofazimine was previously used in a response study on hepatocellular carcinoma together 
with doxorubicin but the poor outcome, together with the toxicity seen in combined therapy, 
suggested that further investigation is needed (Falkson C.I. et al 1999).  
Given the high specificity of the new drugs for Kv1.3, and the low concentrations needed with 
respect to the “old” inhibitors PAP-1 and Psora-4, the compounds could efficiently be used to 
selectively target Kv1.3 high-expressing tissues, also when used in combination with 
chemotherapeutic, to amplify and improve their effects. Combination of a therapeutic drug 
together with a regulator of potassium channel expression (DCA) was recently used and 
showed a significant synergy in the inhibition of endometrial cancer cells proliferation (Xie J. 
et al 2011). Moreover, blockade of hERG channel was found to reduce bone marrow 
mesenchymal stem cell-induced chemotherapeutic resistance in leukemic cells (Pillozzi S. et 
al 2011). Here, I showed that treatment with PAPTP enhances the effect of the 
chemotherapeutic drug cisplatin of more than 50% in melanoma tumor. 
5.6 ROS and synergistic effect with PAP-1 derivatives 
Here, I showed that administration of the antioxidant N-acetylcysteine (NAC) prevents in vivo 
melanoma reduction previously seen upon treatment with Kv1.3 blockers. Particularly, it 
seems that NAC, thanks to its antioxidant capacity, is able to avoid the achievement of the 
reactive oxygen species (ROS) critical threshold needed to induce cell death. This result 
suggests that the reaching of a certain level of ROS is indispensable for the induction of 
apoptosis triggered by the derivatives. 
Although the idea of inducing cell death in malignant cells exploiting their altered redox state 
was proposed more than 10 years ago, it became of relevant application only recently (Kong 
Q. et al 2000). Both exogenous ROS induction and antioxidants inhibition were proposed as 
selective mechanisms to target cancer cells which already display an increased ROS level 
(Szatrowski T.P. et al 1991, Toyokuni S. et al 1995). The first in vivo attempt of using a pro-
oxidant as anticancer agent was done by Nathan and Cohn, who showed that delivery of 
hydrogen peroxide by injection of glucose oxidase particles was able to reduce tumor growth 
(Nathan C.F. et al 1981). Induction of ROS by amitriptyline was shown to induce irreversible 
mitochondrial damage and decrease of antioxidant machinery in different tumor cell lines 
(Cordero M.D. et al 2010). Commonly used chemotherapeutic drugs also induce ROS. The 
combination of the anti-replicative drug 5-fluorouracil (5-FU) and oxaliplatin recently showed 
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to exert an anticancer effect which is linked to increased ROS formation in vitro and in vivo 
(Afzal S. et al 2012). In primary cultured and ex vivo leukemia cells, inhibition of 
mitochondrial respiration by an anti-leukemic agent increased ROS production and enhanced 
the activity of other O2
—
 producing agents (Pelicano H. et al 2003). Also, treatment of acute 
myeloid leukemia cells (AML) with fatty acid palmitate induced oxidative stress and cell 
death without toxicity (Sriskanthadevan S. et al 2015). This happened because AML cells, 
retaining a higher mitochondrial mass without an increase in respiratory chain activity, 
display a lower spare capacity in the electron transport chain (ETC), thus being more 
susceptible to oxidative stress. The observed mechanism was shown to be ROS-dependent, 
since pretreatment with the ROS scavenger NAC blocked cell death. Another example is 
given by the ability of the novel compound Elesclomol to induce oxidative stress in malignant 
melanoma (Kirshner J.R. et al 2008). However, trial III was blocked due to increased 
mortality in double treatments with another compound. Ongoing research is also regarding 
pro-oxidants effects on cancer stem cells (CSC). For example CD13, a marker for semi-
quiescent CSCs in human cancer cell lines and clinical samples, reduces ROS-induced DNA 
damage after genotoxic chemo/radiation stress, thus preventing cells from apoptosis 
(Haraguchi N. et al 2010). Combined therapy with 5-FU and a CD13 inhibitor, which 
suppressed the self-renewing and tumor-initiating ability of dormant CSC, showed drastic 
tumor reduction compared to the treatment with either agent alone. Further, miR-128a was 
used to induce ROS in medulloblastoma SCs to render them more radiosensitive 
(Venkataraman S. et al 2010). The mitosis inhibitor paclitaxel was also used to promote ROS 
through NADPH oxidase enhancement, slowing tumor growth (Alexandre J. et al 2007, 
Ramanathan B. et al 2005). However, it seems that ROS induced by this drug mostly 
accumulate outside the cells rather than in the intracellular milieu of exposed cell, having an 
effect on bystander cells. Enhancement of ROS generation by arsenic trioxide (ARS), which 
impairs the function of the respiratory chain, was also found to increase therapeutic efficacy 
of ionizing radiation in prostate cancer (Chiu H.W. et al 2012). Elevating ROS in pancreatic 
cancer by the use of ARS, retinamide or dithiophene displayed enhancement of mda-7/IL-24 
protein expression and suppressed tumorigenesis in vivo (Lebedeva I.V. et al 2005). The lack 
of killing effect upon treatment with NAC or Tiron underlined the key role of ROS in the 
induction of apoptosis of these cells. Finally, mitochondrially-targeted anticancer drugs (such 
as mitocans) have also been successfully used to selectively induce apoptosis in cancer cells 
by increasing ROS production via targeting of the ETC or the mitochondrial components 
(Ralph S.J. et al 2010). 
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Involvement of ROS through the targeting of mitochondrial channels has been observed and 
exploited in other studies. Caspase-dependent apoptosis through production of ROS by 
VDAC1 overexpression in the OMM has been induced in cancer cells by the anti-cancer 
agent furanonaphthoquinone (FNQ) (Simamura E. et al 2008). On the other hand, 
overexpression of the uncoupling protein-2 (UCP-2) in the IMM has been shown to protect 
cancer cells from oxidative stress, since a depolarizing proton leak is expected to diminish 
superoxide production (Arsenijevic D. et al 2000, Baffy G. et al 2011). UCP-2 overexpression 
also abolished chemotherapeutic induced apoptosis and directly contributed to tumor 
development in an orthotopic model of breast cancer (Ayyasamy V. et al 2011, Derdak Z. et 
al 2008). Mitochondria-derived ROS have been shown to activate Kv1.5 (Caouette D. et al 
2003) and a mitochondria-ROS-Kv1.5 axis-based O2 sensing mechanism has been proposed 
(Michelakis E.D. et al 2002). On the contrary, ROS showed to reduce Kv1.3 current by 
increasing Kv1.3 tyrosine phosphorylation (Cayabyab F.S. et al 2000), whereas ROS 
scavengers reduced basal Kv1.3 phosphorylation level. As well, Szabó and colleagues 
demonstrated that H2O2 was able to inhibit Kv1.3 current in T lymphocytes (Szabo I. et al 
1997). This finding was also supported by the group of Honore, who proved that a generator 
of ROS was able to inhibit the activity of different K
+ 
channels, included Kv1.3 and Kv1.5 
(Duprat F. et al 1995). 
Furthermore, Kv11.1 (hERG channel), which is expressed in a variety of tumors, has been 
suggested to mediate H2O2-induced apoptosis in different cancer cell lines (Wang H. et al 
2002). Interestingly, unlike those in healthy cells, mtBK channels of glioma cells, but not PM 
BK channels, are oxygen sensitive. BK channel openers have been shown to inhibit ROS 
production of isolated rat brain mitochondria (Gu X.Q. et al 2014).  
My in vivo results are an example of how the pharmacological targeting of a mitochondrial 
potassium channel leads to changes in mitochondrial ROS production which synergize with 
the increased ROS level of the malignant cell, selectively inducing cell death on the tumor 
cells.  
5.7 Lymphotoxicity-free tumor apoptosis induction by PAP-1 
derivatives 
My analysis on immune cells shows that PAP-1 derivatives do not alter the relative 
composition of the immune system. One of the most important negative side effects of 
classical chemotherapeutics is that, often, the killing effect targeting fast-proliferating cells 
also affects immune cells. It is accepted that infiltrating cells of the immune system become 
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constituents of tumors, where they can either antagonize or promote it. Among tumor 
promoting inflammatory cells there are T and B cells, macrophages, mast cells and 
neutrophils, which release growth factors such as EGF (epidermal growth factor) and VEGF 
(vascular endothelial growth factor), chemokines and cytokines, and proangiogenic matrix 
degrading proteins such as MMP-9 (matrix metallopeptidase 9) and cysteine protease (Qian 
B.Z. et al 2010). Number of CD4
+
CD25
+
 regulatory T (Treg) cells in tumors and decreased 
ratios of CD8
+
 T cells to Treg cells have been demonstrated to correlate with poor prognosis 
in patients with various cancers (Nishikawa H. et al 2010). In mice, deficiencies of function in 
CD8
+
 cytotoxic T lymphocytes (CTLs) and CD4
+
 Th1 helper T cells lead to increase in tumor 
incidence (Teng M.W. et al 2008). On the other hand, FoxP3 expressing CD4
+
CD25
+
 Treg 
cells have been demonstrated to inhibit anti-tumor immune response (Hansen W. et al 2012). 
B cells have also been shown not always to have a positive contribution to anticancer 
immunity. For example, Shalapour and colleagues demonstrated that a B cell subpopulation 
was able to suppress activation of CD8
+ 
T cells in prostate cancer treated with oxaliplatin 
(Shalapour S. et al 2015). Deletion of B cells increased T-cells infiltration, improving the 
efficacy of the treatment. Different micro-environmental signals can induce macrophages to 
polarize toward a M1 or M2 program. Although M1 phenotype macrophages are thought, 
through IL-2 and IL-23 production, to have an anti-tumor function, M2 macrophages possess 
a high scavenging and tissue repair ability, favoring angiogenesis and tumor progression by 
secretion of IL-10 and transforming-growth factor β (TGF-β) (Sica A. et al 2008). Moreover, 
tumor associated macrophages (TAMs), which represent the major inflammatory component 
of the stroma of many tumors, express many characteristics of M2-polarized macrophages and 
show several pro-tumor functions, including adaptive immunity suppression and matrix 
remodeling ability (Mantovani A. et al 2002, Mantovani A. 2010). High numbers of TAMs 
were correlated with increased tumor vascularization and involvement of lymph node in 
different human tumors (Lewis C.E. et al 2006). The treatment of a B cell lymphoma model 
with CD20 showed to induce M2-phenotype macrophages to increase phagocytosis of 
malignant B cells (Leidi M. et al 2009). Recently, a N1-N2 polarization was also found for 
neutrophils, thus suggesting a functional plasticity of this component, although their role still 
has to be clarified (Fridlender Z.G. et al 2009). 
In this study, I showed that the blocking of Kv1.3 channel by PAP-1 derivatives does not 
change the immune cells subpopulation distribution, thus providing a further advantage on the 
specificity of the drugs. 
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6 SUMMARY 
 
In the first part of my study, I investigated the ability of different Kv1.3 inhibitors, included 
both standard ones (PAP-1, Psora-4 and clofazimine) and PAP-1 derivatives (PEGME, 
PAPTP and PCARBMTP), to induce apoptosis on glioma cell lines.  
My experimental data confirm and extend the knowledge about Kv1.3 expression not only in 
the plasma membrane but also in mitochondria of glioma cells. Moreover, although standard 
inhibitors PAP-1 and Psora-4 only induced 30% cell death, blocking of mtKv1.3 by PAP-1 
derivatives caused a massive apoptosis on these cells. The higher efficacy of the new drugs, 
compared to PAP-1 and Psora-4, has to be ascribed to the engineered PEG (polyethylene 
glycol) and TPP (tetraphenylphosphonium) groups, which confer the inhibitors an increased 
solubility and targeting ability to mitochondria. Clofazimine and PAP-1 derivatives further 
showed to induce the characteristics of mtKv1.3-mediated apoptosis, including cytochrome c 
release, mitochondrial depolarization and ROS increase in glioma cells.  
The pharmacokinetic analysis on the distribution of the new Kv1.3 inhibitors in different 
organs revealed that these compounds are mostly retained in metabolizing organs (liver, 
kidney) but their concentrations decrease within 8h. No accumulation was found in heart and 
brain. On the one hand, this result explained the lack of efficacy of the drugs in the treatment 
of glioma in vivo. This finding suggests that PAP-1 derivatives can be used in the treatment of 
other tumors, such as melanoma. In this case, toxic effects are excluded, since no alterations 
were found in histological tissue samples from organs of treated mice. 
In the second part of my work, I showed that PAP-1 derivatives are effective in the treatment 
of melanoma, inducing 60% up to 90% tumor reduction in an orthotopic mouse model. 
Moreover, I opened insight on the fact that the observed effect of the drugs does not only 
depend on mtKv1.3 expression but also on the ROS status of malignant cells. This finding is 
in accordance with the previous study of Szabó’s group on ex vivo B-CLL cells (Leanza L. et 
al 2013) and suggests further investigation on the possibility of using Kv1.3 inhibitors in 
synergistic action with chemotherapeutic drugs. By analyzing the influence of PAP-1 
derivatives on immune cells subpopulations, no significant alterations were found in the 
number of M1/M2 macrophages, regulatory T cells, neutrophils, B and T lymphocytes within 
the tumor. This result confirms the lack of lymphotoxicity by these drugs, thus contributing to 
derivatives specificity. 
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Concluding, highly specific Kv1.3-dependent apoptosis induction by PAP-1 derivatives was 
found in the treatment of glioma in vitro and melanoma in vivo. Kv1.3 expression level seems 
to synergize together with the altered redox status in malignant cells to provide these effects. 
Thus, selectivity of these drugs, together with safety profile, could be used in the treatment of 
melanoma and other cancers. The possibility of a combined treatment with a 
chemotherapeutic is also suggested. 
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